CA2546401A1 - The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis - Google Patents
The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis Download PDFInfo
- Publication number
- CA2546401A1 CA2546401A1 CA002546401A CA2546401A CA2546401A1 CA 2546401 A1 CA2546401 A1 CA 2546401A1 CA 002546401 A CA002546401 A CA 002546401A CA 2546401 A CA2546401 A CA 2546401A CA 2546401 A1 CA2546401 A1 CA 2546401A1
- Authority
- CA
- Canada
- Prior art keywords
- ctgf
- fibrosis
- receptor
- ctgf receptor
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 76
- 206010016654 Fibrosis Diseases 0.000 title claims abstract description 46
- 230000004761 fibrosis Effects 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 40
- 108010064884 trkA Receptor Proteins 0.000 title claims description 12
- 102000015533 trkA Receptor Human genes 0.000 title claims description 12
- 238000012216 screening Methods 0.000 title description 3
- 101150091877 Ccn2 gene Proteins 0.000 title 1
- 102000005962 receptors Human genes 0.000 claims abstract description 78
- 108020003175 receptors Proteins 0.000 claims abstract description 78
- 239000000018 receptor agonist Substances 0.000 claims abstract description 33
- 229940044601 receptor agonist Drugs 0.000 claims abstract description 33
- 230000004913 activation Effects 0.000 claims abstract description 28
- 238000012360 testing method Methods 0.000 claims abstract description 14
- 102100031168 CCN family member 2 Human genes 0.000 claims abstract 40
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims abstract 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 201000010099 disease Diseases 0.000 claims description 30
- 230000003176 fibrotic effect Effects 0.000 claims description 29
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 24
- 206010012601 diabetes mellitus Diseases 0.000 claims description 24
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 24
- 101001006892 Homo sapiens Krueppel-like factor 10 Proteins 0.000 claims description 23
- 102100027798 Krueppel-like factor 10 Human genes 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 238000003745 diagnosis Methods 0.000 claims description 13
- 206010048654 Muscle fibrosis Diseases 0.000 claims description 12
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 12
- 239000000556 agonist Substances 0.000 claims description 11
- 230000003993 interaction Effects 0.000 claims description 9
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 230000000692 anti-sense effect Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 206010023330 Keloid scar Diseases 0.000 claims description 6
- 206010023421 Kidney fibrosis Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims description 6
- 208000031472 Retinal fibrosis Diseases 0.000 claims description 6
- 206010039710 Scleroderma Diseases 0.000 claims description 6
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 6
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000007882 cirrhosis Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 210000004165 myocardium Anatomy 0.000 claims description 6
- 230000009822 protein phosphorylation Effects 0.000 claims description 6
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 6
- 230000036573 scar formation Effects 0.000 claims description 6
- 210000002027 skeletal muscle Anatomy 0.000 claims description 6
- 230000035578 autophosphorylation Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000002464 receptor antagonist Substances 0.000 claims description 5
- 229940044551 receptor antagonist Drugs 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 148
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 148
- 210000004027 cell Anatomy 0.000 description 47
- 108090000623 proteins and genes Proteins 0.000 description 40
- 102000004169 proteins and genes Human genes 0.000 description 35
- 235000018102 proteins Nutrition 0.000 description 32
- 102000037865 fusion proteins Human genes 0.000 description 15
- 108020001507 fusion proteins Proteins 0.000 description 15
- 238000001262 western blot Methods 0.000 description 15
- 101150111783 NTRK1 gene Proteins 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- 239000012528 membrane Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 230000026731 phosphorylation Effects 0.000 description 9
- 238000006366 phosphorylation reaction Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- -1 alkyl amide Chemical class 0.000 description 7
- 239000013592 cell lysate Substances 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000000074 antisense oligonucleotide Substances 0.000 description 6
- 238000012230 antisense oligonucleotides Methods 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 6
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 101000976713 Homo sapiens Integrin beta-like protein 1 Proteins 0.000 description 5
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 5
- 102100023481 Integrin beta-like protein 1 Human genes 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 101150056950 Ntrk2 gene Proteins 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 229940027941 immunoglobulin g Drugs 0.000 description 5
- 210000003584 mesangial cell Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- 235000002374 tyrosine Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- VOTJUWBJENROFB-UHFFFAOYSA-N 1-[3-[[3-(2,5-dioxo-3-sulfopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VOTJUWBJENROFB-UHFFFAOYSA-N 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 3
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 101150117329 NTRK3 gene Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 108091008611 Protein Kinase B Proteins 0.000 description 3
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 3
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004068 intracellular signaling Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- PTQOJHUHQGPAFD-UHFFFAOYSA-N 2,5,7-trihydroxy-6-methyl-4-oxo-2-phenyl-3h-chromene-8-carbaldehyde Chemical compound C1C(=O)C2=C(O)C(C)=C(O)C(C=O)=C2OC1(O)C1=CC=CC=C1 PTQOJHUHQGPAFD-UHFFFAOYSA-N 0.000 description 2
- ZZUBHVMHNVYXRR-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-2h-chromen-7-ol Chemical compound C1=CC(O)=CC=C1C1=CC2=CC=C(O)C=C2OC1 ZZUBHVMHNVYXRR-UHFFFAOYSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102100020944 Integrin-linked protein kinase Human genes 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 206010067953 Radiation fibrosis Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000011544 gradient gel Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 108010059517 integrin-linked kinase Proteins 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- RCGXNDQKCXNWLO-WLEIXIPESA-N (2r)-n-[(2s)-5-amino-1-[[(2r,3r)-1-[[(3s,6z,9s,12r,15r,18r,19s)-9-benzyl-15-[(2r)-butan-2-yl]-6-ethylidene-19-methyl-2,5,8,11,14,17-hexaoxo-3,12-di(propan-2-yl)-1-oxa-4,7,10,13,16-pentazacyclononadec-18-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopent Chemical compound N([C@@H](CCCN)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H]1C(N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NC(/C(=O)N[C@H](C(=O)O[C@H]1C)C(C)C)=C\C)C(C)C)[C@H](C)CC)=O)C(=O)[C@H]1CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CCCC(C)C)C(C)C)[C@@H](C)O)C(C)C)C(C)C RCGXNDQKCXNWLO-WLEIXIPESA-N 0.000 description 1
- SNAJPQVDGYDQSW-DYCFWDQMSA-N (4r,7s,10r,13s,16r)-7-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-16-[[(2r)-2-amino-3-phenylpropanoyl]amino]-13-[(4-hydroxyphenyl)methyl]-10-(1h-indol-3-ylmethyl)-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxami Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC1=O)C(=O)N[C@@H]([C@H](O)C)C(N)=O)C1=CC=CC=C1 SNAJPQVDGYDQSW-DYCFWDQMSA-N 0.000 description 1
- KQJSQWZMSAGSHN-UHFFFAOYSA-N (9beta,13alpha,14beta,20alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(O)=C2C KQJSQWZMSAGSHN-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- YJZSUCFGHXQWDM-UHFFFAOYSA-N 1-adamantyl 4-[(2,5-dihydroxyphenyl)methylamino]benzoate Chemical compound OC1=CC=C(O)C(CNC=2C=CC(=CC=2)C(=O)OC23CC4CC(CC(C4)C2)C3)=C1 YJZSUCFGHXQWDM-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- AAALVYBICLMAMA-UHFFFAOYSA-N 4,5-dianilinophthalimide Chemical compound C=1C=CC=CC=1NC=1C=C2C(=O)NC(=O)C2=CC=1NC1=CC=CC=C1 AAALVYBICLMAMA-UHFFFAOYSA-N 0.000 description 1
- QSFREBZMBNRGOK-UHFFFAOYSA-N 4-[(2,5-dihydroxyphenyl)methylamino]benzoic acid methyl ester Chemical compound C1=CC(C(=O)OC)=CC=C1NCC1=CC(O)=CC=C1O QSFREBZMBNRGOK-UHFFFAOYSA-N 0.000 description 1
- ULTTYPMRMMDONC-UHFFFAOYSA-N 5-[(2,5-dihydroxyphenyl)methyl-[(2-hydroxyphenyl)methyl]amino]-2-hydroxybenzoic acid Chemical class C1=C(O)C(C(=O)O)=CC(N(CC=2C(=CC=CC=2)O)CC=2C(=CC=C(O)C=2)O)=C1 ULTTYPMRMMDONC-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
- 101100166589 Arabidopsis thaliana CCX2 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 101100222854 Bacillus subtilis (strain 168) czcO gene Proteins 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010082830 CEP 2563 Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- AQKDBFWJOPNOKZ-UHFFFAOYSA-N Celastrol Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(=O)C2C AQKDBFWJOPNOKZ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- PBEVPBFDKPJIOM-HQKLUXGTSA-N Cl.Cl.C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@](OC)(COC(=O)CCNC(=O)[C@@H](N)CCCCN)[C@]4(C)O1 Chemical compound Cl.Cl.C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@](OC)(COC(=O)CCNC(=O)[C@@H](N)CCCCN)[C@]4(C)O1 PBEVPBFDKPJIOM-HQKLUXGTSA-N 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010066499 EGF-genistein Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 229940124783 FAK inhibitor Drugs 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100537961 Methanosarcina mazei (strain ATCC BAA-159 / DSM 3647 / Goe1 / Go1 / JCM 11833 / OCM 88) trkA2 gene Proteins 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
- 241000425385 Nepha Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102000049873 Smad7 Human genes 0.000 description 1
- 108700031279 Smad7 Proteins 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 108010046910 brain-derived growth factor Proteins 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000008508 epithelial proliferation Effects 0.000 description 1
- SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000011773 genetically engineered mouse model Methods 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000005086 glomerual capillary Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000004001 inositols Chemical class 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 239000007926 intracavernous injection Substances 0.000 description 1
- 108010091711 kahalalide F Proteins 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 108091006026 monomeric small GTPases Proteins 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- ZTFBIUXIQYRUNT-MDWZMJQESA-N mubritinib Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC(COC=2C=CC(CCCCN3N=NC=C3)=CC=2)=CO1 ZTFBIUXIQYRUNT-MDWZMJQESA-N 0.000 description 1
- UOEJSOXEHKCNAE-UHFFFAOYSA-N n-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide Chemical compound C1=C(NC=2N=C(C=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC=C1 UOEJSOXEHKCNAE-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229950009919 saracatinib Drugs 0.000 description 1
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000007847 structural defect Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009495 transient activation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 101150025395 trkA gene Proteins 0.000 description 1
- 101150113435 trkA1 gene Proteins 0.000 description 1
- 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
The invention provides a method for identifying and/or making compounds for use in reducing and/or preventing fibrosis, comprising the steps: providing a CTGF receptor; providing a test sample; providing a CTGF receptor agonist;
exposing the CTGF receptor to the test sample; subsequently or simultaneously exposing the CTGF receptor to the CTGF receptor agonist; detecting and/or measuring the amount of CTGF receptor activation; comparing the amount of CTGF
receptor activation detected and/or measured in the presence of the test sample with the amount of CTGF receptor activation detected and/or measured in the absence of a test sample; determining if a compound reduces and/or prevents fibrosis on the basis that it causes no increase or a decrease in CTGF receptor activation. There is also provided compounds for reducing and/or preventing fibrosis and uses of such compounds.
exposing the CTGF receptor to the test sample; subsequently or simultaneously exposing the CTGF receptor to the CTGF receptor agonist; detecting and/or measuring the amount of CTGF receptor activation; comparing the amount of CTGF
receptor activation detected and/or measured in the presence of the test sample with the amount of CTGF receptor activation detected and/or measured in the absence of a test sample; determining if a compound reduces and/or prevents fibrosis on the basis that it causes no increase or a decrease in CTGF receptor activation. There is also provided compounds for reducing and/or preventing fibrosis and uses of such compounds.
Description
~I~L~GICAL 1VIATERIALS ANNA USES THEIaEOF
s The presently claimed invention relates to methods of identifying and/or making compounds for use in the reduction and/or prevention of fibrosis.
The invention also relates to compounds for reducing and/or preventing fibrosis and to the use of such compounds.
to When biological tissue is injured, both the injury and the associated inflammatory response can cause the death of cells. When cell death occurs, new tissue is synthesised to replace the dead or dying cells. The synthesis of new tissue falls under two categories, the regeneration of specialised cells ~s and an increase in connective tissue. In some pathological conditions, the connective tissue increase dominates the healing process, leading to the formation of fibrotic tissue. In fibrosis, the new tissue has repaired any structural defect in the tissue, but has impaired its own function by replacing the specialised cells by connective tissue and connective tissue-2o producing cells.
Whether fibrosis occurs, or indeed the extent of the fibrosis, is influenced by a variety of factors, including the nature, severity and location of the injury to be healed. Fibrosis is most commonly known as scars on the 2s surface of the skin, where it is relatively un-troublesome, except in scarring over large areas. However, fibrosis can also occur in the tissues of internal organs e.g. liver, lung and kidney. In most cases, it is fibrosis in these areas that is most serious because the specialised activity of that organ is impaired. In the most extreme cases organ failure or death can occur 3o because of that impairment.
An example of the importance of fibrosis in the disease-state is demonstrated by the occurrence of fibrosis of the kidney (diabetic nephropathy) in diabetes mellitus, a disease now reaching epidemic s proportions worldwide.
The incidence of diabetes mellitus has undergone a global increase in recent years. In particular this is due to a dramatic increase in type 2 diabetes (late-onset diabetes) (Silink M (2002), Horm. Res. 57 (Suppl 1) pp. 1-5).
1o Diabetes mellitus is closely linked to a number of secondary complications, especially microvascular related complications. These complications, including the fibrotic condition nephropathy, usually develop a number of years after the onset of diabetes.
1s Diabetic nephropathy is characterised by excessive deposition of extracellular matrix proteins in the mesangium and basement membrane of the glomerulus and in the renal tubulointerstitium.
Genetic background is thought to be important in determining susceptibility 2o to diabetic nephropathy (DN) (Quinn M et al., (1996) Diabetologica 39 pp 940-945), but the crucial initiating factor is believed to be exposure of tissues to chronic hyperglycaemia (UI~PDS Group, (1998) Lancet 352 pp.
837-853). The prevalence of nephropathy varies according to geographical location, type of diabetes, and the length of time since diagnosis.
2s Notwithstanding influencing factors, the prevalence of diabetic nephropathy is predicted to increase in the decades ahead (Bagust A et al. (2002) Diabetes Med 9.9 (Suppl 4): ppl-5). Diabetic nephropathy is a major cause of end-stage renal disease, and new therapeutic approaches are required to limit its development.
s The presently claimed invention relates to methods of identifying and/or making compounds for use in the reduction and/or prevention of fibrosis.
The invention also relates to compounds for reducing and/or preventing fibrosis and to the use of such compounds.
to When biological tissue is injured, both the injury and the associated inflammatory response can cause the death of cells. When cell death occurs, new tissue is synthesised to replace the dead or dying cells. The synthesis of new tissue falls under two categories, the regeneration of specialised cells ~s and an increase in connective tissue. In some pathological conditions, the connective tissue increase dominates the healing process, leading to the formation of fibrotic tissue. In fibrosis, the new tissue has repaired any structural defect in the tissue, but has impaired its own function by replacing the specialised cells by connective tissue and connective tissue-2o producing cells.
Whether fibrosis occurs, or indeed the extent of the fibrosis, is influenced by a variety of factors, including the nature, severity and location of the injury to be healed. Fibrosis is most commonly known as scars on the 2s surface of the skin, where it is relatively un-troublesome, except in scarring over large areas. However, fibrosis can also occur in the tissues of internal organs e.g. liver, lung and kidney. In most cases, it is fibrosis in these areas that is most serious because the specialised activity of that organ is impaired. In the most extreme cases organ failure or death can occur 3o because of that impairment.
An example of the importance of fibrosis in the disease-state is demonstrated by the occurrence of fibrosis of the kidney (diabetic nephropathy) in diabetes mellitus, a disease now reaching epidemic s proportions worldwide.
The incidence of diabetes mellitus has undergone a global increase in recent years. In particular this is due to a dramatic increase in type 2 diabetes (late-onset diabetes) (Silink M (2002), Horm. Res. 57 (Suppl 1) pp. 1-5).
1o Diabetes mellitus is closely linked to a number of secondary complications, especially microvascular related complications. These complications, including the fibrotic condition nephropathy, usually develop a number of years after the onset of diabetes.
1s Diabetic nephropathy is characterised by excessive deposition of extracellular matrix proteins in the mesangium and basement membrane of the glomerulus and in the renal tubulointerstitium.
Genetic background is thought to be important in determining susceptibility 2o to diabetic nephropathy (DN) (Quinn M et al., (1996) Diabetologica 39 pp 940-945), but the crucial initiating factor is believed to be exposure of tissues to chronic hyperglycaemia (UI~PDS Group, (1998) Lancet 352 pp.
837-853). The prevalence of nephropathy varies according to geographical location, type of diabetes, and the length of time since diagnosis.
2s Notwithstanding influencing factors, the prevalence of diabetic nephropathy is predicted to increase in the decades ahead (Bagust A et al. (2002) Diabetes Med 9.9 (Suppl 4): ppl-5). Diabetic nephropathy is a major cause of end-stage renal disease, and new therapeutic approaches are required to limit its development.
The pathology of diabetic nephropathy is similar in types 1 and 2 diabetes.
Both types of diabetes are associated with similar ultrastructural changes occurring in kidney glomeruli (Osterby R, (1992) Diabetologica 35 pp 803-812). The glomerular basement membrane increases in thickness, and the s extracellular matrix of the inesangium expands.
It is expansion of the mesangium that is thought to be the main cause of reduced renal function in diabetic nephropathy (Steffes M et al. (1989) Diabetes 38 pp1077-1081). As the mesangial matrix expands, it impinges on glomerular capillaries, reducing the surface available for filtration and narrowing or occluding the lumen. Tubulointerstitial fibrosis also occurs in diabetic nephropathy, in addition to glomerulosclerosis. The progressive loss of renal function correlates with the occurrence of advancing interstitial fibrosis in other renal disorders (Risdon R et al. (1968) Lancet 2 7564 is pp363-366).
Fibrotic disease is commonly associated with an imbalance in growth factors and hormones, which in turn influence the production of protein expression. The abnormal protein expression in turn leads to the formation of fibrosis. For example, fibrosis is commonly influenced by an increase in transforming growth factor-(~ present in the fibrotic tissue.
Fibrosis is one of the largest groups of disorders for which there is no effective therapy, in part because the mechanism underlying these disorders 2s is influenced by a variety of factors and exact cellular mechanisms have not been elucidated. Therefore, there is a laclc of understanding of which, or the nature of molecular targets which may provide targets around which anti-fibrotic therapies may be based.
In the case of diabetic nephropathy, studies have shown that glucose can induce matrix synthesis, at least in part, by the actions of transforming growth factor-(3 (TGF-Vii) (Ziyadeh F et al. (2000) P~oc Natl Acad Sci USA
97 pp. 8015-8020).
s However, TGF-~i has a number of physiological roles including involvement in immunity and epithelial proliferation (McCartney-Francis N
et al. (1998) Iut. Rev. If~zmuhol. 16 pp. 553-580). These varying physiological effects mean that TGF-~ is unlikely to be a clinically 1o advantageous target. Blocking the actions of TGF-~i may have multiple effects on the organism, causing unwanted and potentially serious side effects.
Transforming growth factor-~i causes fibrosis by the direct induction of is collagen and matrix synthesis. Additionally, TGF-~i is also able to induce the expression of other molecules that take part in andlor influence the pathways causing fibrosis. One such protein is connective tissue growth factor (CTGF), which induces proliferation, collagen synthesis and chemotaxis in mesenchymal cells (Moussad E et al. (2000) Molec Genet 2o Metab. 71 pp.276-292). CTGF (CCN2) is a 38 kDa secreted protein with multiple domains, encoded by an immediate-early gene and is a member of the CCN protein family (Bork et al. (1993) Feb,r Lett. 327 pp 125-130;
Perbal et al. (2001) Mol. Pathol. 54 pp 57-79). However, the molecular mechanisms) by which it functions have not been fully elucidated. The 25 presence of multiple domains in CTGF suggests that it interacts with a plurality of other factors. CTGF has been shown to directly bind BMP4 and TGF-~3 through its von Willebrand type C domain, leading to inhibition of BMP and enhancement of TGF-~ signalling (Abreu et al. (2002) Nat. Cell.
Biol. 4 pp. 599-604).
Both types of diabetes are associated with similar ultrastructural changes occurring in kidney glomeruli (Osterby R, (1992) Diabetologica 35 pp 803-812). The glomerular basement membrane increases in thickness, and the s extracellular matrix of the inesangium expands.
It is expansion of the mesangium that is thought to be the main cause of reduced renal function in diabetic nephropathy (Steffes M et al. (1989) Diabetes 38 pp1077-1081). As the mesangial matrix expands, it impinges on glomerular capillaries, reducing the surface available for filtration and narrowing or occluding the lumen. Tubulointerstitial fibrosis also occurs in diabetic nephropathy, in addition to glomerulosclerosis. The progressive loss of renal function correlates with the occurrence of advancing interstitial fibrosis in other renal disorders (Risdon R et al. (1968) Lancet 2 7564 is pp363-366).
Fibrotic disease is commonly associated with an imbalance in growth factors and hormones, which in turn influence the production of protein expression. The abnormal protein expression in turn leads to the formation of fibrosis. For example, fibrosis is commonly influenced by an increase in transforming growth factor-(~ present in the fibrotic tissue.
Fibrosis is one of the largest groups of disorders for which there is no effective therapy, in part because the mechanism underlying these disorders 2s is influenced by a variety of factors and exact cellular mechanisms have not been elucidated. Therefore, there is a laclc of understanding of which, or the nature of molecular targets which may provide targets around which anti-fibrotic therapies may be based.
In the case of diabetic nephropathy, studies have shown that glucose can induce matrix synthesis, at least in part, by the actions of transforming growth factor-(3 (TGF-Vii) (Ziyadeh F et al. (2000) P~oc Natl Acad Sci USA
97 pp. 8015-8020).
s However, TGF-~i has a number of physiological roles including involvement in immunity and epithelial proliferation (McCartney-Francis N
et al. (1998) Iut. Rev. If~zmuhol. 16 pp. 553-580). These varying physiological effects mean that TGF-~ is unlikely to be a clinically 1o advantageous target. Blocking the actions of TGF-~i may have multiple effects on the organism, causing unwanted and potentially serious side effects.
Transforming growth factor-~i causes fibrosis by the direct induction of is collagen and matrix synthesis. Additionally, TGF-~i is also able to induce the expression of other molecules that take part in andlor influence the pathways causing fibrosis. One such protein is connective tissue growth factor (CTGF), which induces proliferation, collagen synthesis and chemotaxis in mesenchymal cells (Moussad E et al. (2000) Molec Genet 2o Metab. 71 pp.276-292). CTGF (CCN2) is a 38 kDa secreted protein with multiple domains, encoded by an immediate-early gene and is a member of the CCN protein family (Bork et al. (1993) Feb,r Lett. 327 pp 125-130;
Perbal et al. (2001) Mol. Pathol. 54 pp 57-79). However, the molecular mechanisms) by which it functions have not been fully elucidated. The 25 presence of multiple domains in CTGF suggests that it interacts with a plurality of other factors. CTGF has been shown to directly bind BMP4 and TGF-~3 through its von Willebrand type C domain, leading to inhibition of BMP and enhancement of TGF-~ signalling (Abreu et al. (2002) Nat. Cell.
Biol. 4 pp. 599-604).
CTGF has also been shown to bind to integrins (Babic et al. (1999) Mol.
Cell Biol. 19 pp.3811-3815) and it is possible that this interaction is important in mediating some of the cellular phenomena that CTGF induces.
s CTGF is over-expressed in a variety of fibrotic disorders, including diabetic nephropathy (Wahab N et al. (2001) Biochefn J. 359 pp.77-87). In fact, increasing levels of CTGF expression have been shown to correlate with increasing severity and speed of progression of diabetic nephropathy (Ito Y
to et al. (1998) .Kidney hZt. 53 pp.853-886).
Hence, CTGF may be a potentially useful molecular indicator of the fibrotic response. CTGF has not yet been shown to directly induce renal fibrosis in vivo, but, when injected subcutaneously along with TGF-~, induces 1s sustained dermal fibrosis in rats (Mori T et al. (1999) J. Cell. Physiol.
pp 153-159).
In the process of developing this invention, the inventors have demonstrated that CTGF interacts with a cellular receptor, the TrkA receptor, in order to 2o induce intracellular signalling cascades related to the formation of fibrosis.
There axe three Trk receptor tyrosine lcinase genes (TrkA, TrkB and TrkC).
On binding its ligand, the Trk receptor dimerizes and autophosphorylates, leading to the activation of several small G proteins, including Ras, Rap-l, ~s and the Cdc 42-Rac-Rho family, as well as of pathways regulated by MAP
kinase, PI3-kinase, and phospholipase C-y (PLC y) (Segal, 2003). Activated Trk receptors also interact, directly or indirectly, with a variety of cytoplasmic adaptor proteins to produce a number of biological responses including, cell proliferation and survival; axonal and dendritic growth, and remodelling; assembly and remodelling of cytoskeleton; membrane trafficking and fusion; and synapse formation, function, and plasticity (Huang E and Reichardt L, (2003) Afzuu. Rev. Biochem. 72 pp. 609-642).
s The work by the inventors described in the examples, has shown that Trk tyrosine kinase activity is required for the CTGF-dependent induction of intracellular signalling molecules implicated in fibrosis. This work has led to the establishment of a method of identifying and making compounds that can interact with the CTGF receptor and/or an agonist of the CTGF receptor 1o in order to reduce or prevent fibrosis.
Therefore, in a first aspect of the invention is provided a method for identifying and/or making compounds for use in reducing and/or preventing fibrosis, comprising the steps:
(a) providing a CTGF receptor (b) providing a test sample (c) providing a CTGF receptor agonist (d) exposing the CTGF receptor to the test sample (e) subsequently or simultaneously exposing the CTGF receptor to the 2s CTGF receptor agonist (f) detecting and/or measuring the amount of CTGF receptor activation (g) comparing the amount of CTGF receptor activation in the presence of a test sample to the amount of CTGF receptor activation detected and/or measured in the absence of a test sample;
s (h) determining if a compound reduces and/or prevents fibrosis on the basis that it causes no increase or a decrease in CTGF receptor activation.
By "CTGF receptor agonist" we mean a compound acting at the CTGF
receptor to produce an effect that is substantially the same as that of the 1o effect produced by CTGF interacting with the receptor. We also include derivatives, analogues and fragments of CTGF receptor agonists that are capable of producing substantially the same effect as CTGF interacting with the CTGF receptor. CTGF receptor agonists, other than CTGF itself, can be readily identified by measurement and/or detection of CTGF receptor 1s autophosphorylation, receptor induced protein phosphorylation and TIEG
expression using the methods presented in Example 1.
By "derivative" we mean a CTGF receptor agonist compound, additionally having at least one chemical modification of one or more of its amino acid 2o side groups, a-carbon atoms, terminal amino group, or terminal carboxylic acid group. A chemical modification includes adding chemical moieties, creating new bonds, and removing chemical moieties. Modifications at amino acid side groups include acylation of lysine e-amino groups, N-allcylation of arginine, histidine, or lysine, alkylation of glutamic or aspartic 2s carboxylic acid groups, and deamidation of glutamine or asparagine.
Modifications of the terminal amino include the des-amino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications. Modifications of the terminal carboxy group include the amide, lower alkyl amide, dialkyl amide, and lower alkyl ester modifications. A lower alkyl is a C 1 -C4 alkyl.
3o Furthermore, one or more side groups, or terminal groups, may be protected by protective groups l~n.own to the ordinarily spilled protein chemist. The a-carbon of an. amino acid may be mono- or di-methylated.
By "analogue" we mean a CTGF receptor agonist having a modification s including one or more amino acid substitutions, deletions, inversions, or additions and capable of producing an effect that is substantially the same as that of the effect produced by CTGF interacting with the receptor.
By "fragment" we mean a portion of a CTGF receptor agonist capable of 1o producing an effect that is substantially the same as that of the effect produced by CTGF interacting with the receptor.
Optionally the method further comprises the step of isolating the compound which is capable of reducing and/or preventing fibrosis. The isolated 15 compound may then optionally be formulated into a composition further comprising a pharmaceutically acceptable carrier, excipient and/or diluent.
Preferably, CTGF receptor activation is detected and/or measured by detecting andlor measuring at least one of the following activities: CTGF
2o receptor autophosphorylation, CTGF receptor-induced protein phosphorylation or CTGF induced expression of TIEG. Typical methods of measuring these activities are provided in Examples 1 and 2.
Preferably the CTGF receptor agonist is CTGF.
Preferably the CTGF receptor is the TrlcA receptor.
Conveniently the compound affects directly the interaction between the CTGF receptor and an agonist thereof. In other words, the compound interacts directly with the CTGF receptor or agonist thereof in order to reduce the activation of the CTGF receptor.
Alternatively, the compound affects indirectly the interaction between the s CTGF receptor and an agonist thereof. In other words, the compound interacts with the CTGF receptor or agonist thereof indirectly via at least one further compound in order to reduce the activation of the CTGF
receptor.
1o Conveniently, the compound identified and/or made by the method described above is an antagonist of a tyrosine kinase.
By "antagonist" we mean a compound acting at the CTGF receptor to inhibit and/or prevent the effect produced by CTGF or a CTGF receptor 1s agonist interacting with the receptor. We also include derivatives, analogues and fragments of CTGF receptor antagonists that are capable of preventing and/or inhibiting the effect of CTGF and/or a CTGF receptor agonist interacting with the CTGF receptor. CTGF receptor antagonists, can be readily identified by measurement and/or detection of CTGF receptor 2o autophosphorylation, receptor induced protein phosphorylation and TIEG
expression using the methods presented in Example 1.
In a second aspect of the invention there is provided a compound for use in the reduction and/or prevention of fibrosis characterised in that it inhibits 2s and/or prevents CTGF receptor activation; and more preferably inhibits and/or prevents at least one of the following activities: CTGF receptor autophosphorylation; CTGF receptor-induced protein phosphorylation;
and/or induction of TIEG.
Preferably the compound is identified and/or made by the method of the first aspect of the invention.
Conveniently, the compound is at least one selected from polypeptides, antibody molecules and antisense nucleotides. Preferably the compound is an antibody molecule.
The term "antibody molecule" shall be talcen to refer to any one of an antibody, an antibody fragment, or antibody derivative. It is intended to to embrace wildtype antibodies, synthetic antibodies, recombinant antibodies or antibody hybrids, such as, but not limited to, a single-chain modified antibody molecule produced by phage-display of immunoglobulin light and/or heavy chain variable and/or constant regions, or other immunointeractive molecule capable of binding to an antigen in an is immunoassay format that is known to those skilled in the art.
The term "antibody derivative" refers to any modified antibody molecule that is capable of binding to an antigen in an immunoassay format that is known to those skilled in the art, such as a fragment of an antibody (e.g. Fab 20 or Fv fragment), or a modified antibody molecule that is modified by the addition of one or more amino acids or other molecules to facilitate coupling the antibodies to another peptide or polypeptide, to a large carrier protein or to a solid support (e.g. the amino acids tyrosine, lysine, glutamic acid, aspartic acid, cysteine and derivatives thereof, NHZ-acetyl groups or 2s COOH-terminal amido groups, amongst others).
By "antisense oligonucleotides" we mean single-stranded nucleic acids, which can specifically bind to a complementary nucleic acid sequence. By binding to the appropriate target sequence, an RNA-RNA, a DNA-DNA, or 3o RNA-DNA duplex is formed. These nucleic acids are often termed "antisense" because they are complementary to the sense or coding strand of the gene. Recently, formation of a triple helix has proven possible where the oligonucleotide is bound to a DNA duplex. It was found that oligonucleotides could recognise sequences in the major groove of the DNA
s double helix. A triple helix was formed thereby. This suggests that it is possible to synthesise sequence-specific molecules which specifically bind double-stranded DNA via recognition of major groove hydrogen binding sites.
to By binding to the target nucleic acid, the above oligonucleotides can inhibit the function of the target nucleic acid. This could, for example, be a result of blocking the transcription, processing, poly(A)addition, replication, translation, or promoting inhibitory mechanisms of the cells, such as promoting RNA degradations.
Antisense oligonucleotides are prepared in the laboratory and then introduced into cells, for example by microinjection or uptake fiom the cell culture medium into the cells, or they are expressed in cells after transfection with plasmids or retroviruses or other vectors carrying an antisense gene.
Alternatively, the compound is a tyrosine kinase receptor inhibitor.
Preferably the tyrosine kinase inhibitor is selected from the group consisting of BSF-466895, AP-23451, AP-23464, AP-23485, AZD-0530, AP-22408, 2s RG-13022, RG-13291, RG-14620, RP 53801, CEP-075, CEP-2563 dihydrochloride, CHIR-200131, CHIR-258, c jun kinase, I~ST-638, KF-250706, MNAC- .13, anti-EphA2 Mabs, MLN-608, AG-957, lavendustin A
analogues, NSC-330507, NSC-680410, phenylalanine derivatives, SH2 inhibitors, AG-1295, EGF-genistein, erbstatin, genistein, neuT Mab, PPl, 3o TT-232, CGP-52411, CGP-53716, CGP-57148, imatinib, NVP-AAK980-NX, NV-50, phenoxodiol, FAK inhibitors, IGF-1 , Met receptor inhibitors, TIE-2 inhibitors, CP-X64959, PN-355, CP-127374, FCE-26806, FGFR-3 inhibitors, Met RTK antagonists, PD-171026, PD-173956, PD-180970, Src non-RTK antagonists, kahalalide F, CCX2, celastrol, TAK-165 ,TG-100-13, s TG-100-96, desmal, U3-1566 and SKI-606.
Preferably the compound is a CTGF receptor antagonist.
In a third aspect of the invention there is provided a compound of the to second aspect of the invention for use in the treatment and/or prevention and/or diagnosis of a fibrotic disease.
Preferably the compound of the second aspect of the invention is used in the manufacture of a medicament for the treatment and/or prevention and/or is diagnosis of a fibrotic disease.
Conveniently the fibrotic disease is one selected from diabetic nephropathy, non-diabetic kidney fibrosis, lung fibrosis, liver fibrosis (cirrhosis), skeletal muscle fibrosis, cardiac muscle fibrosis, atherosclerosis, systemic sclerosis, 2o scleroderma, retinal fibrosis, radiation fibrosis, keloid scar formation and cancer-associated fibrosis Preferably the disease is diabetic nephropathy.
25 In a fourth aspect of the invention there is provided a method of treating and/or preventing fibrotic disease comprising administering a therapeutically or prophylactically effective dose, or plurality of doses, of a compound identified and/or made according to the method of the first aspect of the invention.
Conveniently the fibrotic disease is one selected from diabetic nephropathy, non-diabetic kidney fibrosis, lung fibrosis, liver fibrosis (cirrhosis), skeletal muscle fibrosis, cardiac muscle fibrosis, atherosclerosis, systemic sclerosis, scleroderma, retinal fibrosis, radiation fibrosis, keloid scar formation and s cancer-associated fibrosis Preferably the disease is diabetic nephropathy.
In a fifth aspect of the invention there is provided a use of an agent capable Io of binding to a CTGF receptor agonist in the treatment and/or prevention and/or diagnosis of a fibrotic disease.
In a sixth aspect of the invention there is provided a use of an agent capable of binding to a CTGF receptor agonist in the manufacture of a medicament 1s for the treatment and/or prevention and/or diagnosis of a fibrotic disease.
Preferably, the fibrotic disease is selected from one or more of diabetic nephropathy, no-diabetic kidney fibrosis, lung fibrosis, liver fibrosis (cirrhosis), skeletal muscle fibrosis, cardiac muscle fibrosis, atherosclerosis, 2o systemic sclerosis, scleroderma, retinal fibrosis, radiation induced fibrosis keloid scar formation and cancer-associated fibrosis.
In a seventh aspect of the invention there is provided a use of an agent capable of binding to a CTGF receptor agonist in a method of reducing 2s and/or preventing binding of a CTGF receptor agonist to a CTGF receptor i~c vivo or ih vita°o.
By "an agent capable of binding to a CTGF receptor agonist" we include a compound, nucleic acid, polypeptide or antibody that is capable of 3o physically associating with a CTGF receptor agonist. Binding between such an agent and a CTGF receptor agonist may occur by ionic, electrostatic and/or covalent interaction. Preferably, the binding of an agent to a CTGF
receptor agonist will reduce and/or prevent the ability of the CTGF receptor agonist to bind to and/or associate with and/or activate a CTGF receptor.
s Preferably, in the seventh aspect of the invention the agent capable of binding to a CTGF receptor agonist is a GTGF receptor. Alternatively, the agent capable of binding to a CTGF receptor agonist is a CTGF receptor joined to the Fc-region of an iinmunoglobulin.
By "Fc-region" we include the "fragment crystallisable" region of an antibody. By "immunoglobulins" we include polypeptides comprising one or more immunoglobulin complementarity-determining region (CDR), such as antibodies, B cell receptors or T cell receptors, or fragments thereof.
Is Preferably, the immunoglobulin is an antibody. More preferably, the immunoglobulin is IgG.
Preferably, in the seventh aspect of the invention there is provided a use wherein the CTGF receptor is the TrkA receptor. Alternatively, the CTGF
2o receptor is a soluble form of the TrkA receptor.
It will be understood that the term "soluble form" includes a form a form of a polypeptide that is not associated with or inserted in the membrane of a cell and which can exist in solution without aggregating.
Preferably, in the fifth, sixth and seventh aspects of the invention the CTGF
agonist is CTGF.
In an eighth aspect of the invention there is provided a nucleic acid encoding the Trl~A receptor joined to an Fc-region of an im~nunoglobulin.
In a ninth aspect of the invention there is provided a vector containing a nucleic acid according to the eighth aspect of the invention.
s In a tenth aspect of the invention there is provided a polypeptide comprising the TrkA receptor joined to an Fc-region of an immunoglobulin.
In an eleventh aspect of the invention there is provided a cell containing a nucleic acid according to the eighth aspect of the invention and/or a vector to according to the ninth aspect of the invention and/or a polypeptide according to the tenth aspect of the invention.
In a twelfth aspect of the invention there is provided a pharmaceutical composition comprising a nucleic acid according to the eighth aspect of the 1s invention and/or a vector according to the ninth aspect of the invention and/or a polypeptide according to the tenth aspect of the invention and/or a cell according to the eleventh aspect of the invention, and a pharmaceutically acceptable carrier or exipient, the nucleic acid and/or the vector and/or the polypeptide and/or the cell being present in an effective 2o amount to treat and/or prevent and/or diagnose a fibrotic disease.
By "effective amount" we include an amount that is sufficient to treat and/or prevent and/or diagnose a fibrotic disease. An effective amount may be determined by use of methods known to those in the art.
Examples embodying certain preferred aspects of the invention will now be described with reference to the following figures in which:-Figure 1 - CTGF activates intracellular signalling pathways Serum-starved human mesangial cells (HMC) incubated in the presence of CTGF/VS fusion protein for the periods of time indicated. Equal amounts of cellular lysate protein were subjected to SDS=PAGE and analysed by Western blotting using phospho-specific antibodies against the constituent s proteins of (A) the MAPK pathway, (B) JNK, and (C) PKB and CamKII. (3-actin is shown as a marker for equal protein loading. D) Cells were grown on coverslips and serum-starved for 48 hours prior to incubation in medium in the absence (a) and (c), or presence of 40 ng/ml CTGF-fusion protein (b) and (d) for 30 min. Cells were fixed, permeabilized, probed with anti-1o phospho PKC 8 (a) and (b) and PKC a (c) and (d) primary antibodies, and then with fiuorescein-conjugated secondary antibody. Results are representative of three separate experiments.
Figure 2 - CTGF induces tyrosine phosphorylation of different proteins 1s Serum-starved HMC were incubated in the presence of 40 ng/ml CTGF/VS
fusion protein for the periods of time indicated. Equal amounts of cellular lysate protein were subjected to SDS-PAGE and analysed by Western blotting using anti-phosphotyrosine antibody. Results are representative of 2o three separate experiments.
Figure 3 - CTGF interacts with I~MfC surface proteins CTGF/VS fusion protein was allowed to bind to the cell surface, and then 25 chemically cross-linked to its ligands with BS3, after which a membrane-enriched fraction was prepared from the cells. Cross-linked CTGF
complexes were immunoprecipitated using rabbit anti-CTGF antibody, resolved by SDS-PAGE, and analysed by Western blotting using chiclcen anti-CTGF antibody (lane 2). The cross-linking step was omitted for some 3o cultures (lane 1). Results are representative of three sepaxate experiments.
Figure 4 - CTGJF interacts with TrkA and p75NTR in IBC
(A) Serum-starved HMC were incubated in the absence (lane 1) or presence s (lane 2) of CTGF/VS fusion protein (40 ng/ml) for 15 min, after which cell lysates were prepared in RIPA buffer. Equal amounts of lysate protein were immunoprecipitated using anti-phosphotyrosine beads.
Bound proteins were resolved by SDS-PAGE and analysed by Western blotting using an antibody against TrkA.
to (B) HMC were incubated in the absence (lane 1) or presence (lane 2) of His tagged-CTGF/VS fusion protein (200 ng/ml) for 2 h at 4°C to allow binding to cell surface receptors, after which the protein was chemically cross-linked with DTSSP. A membrane-enriched fraction was prepared 1s and solubilised. Equal amounts of solubilised protein were incubated with metal affinity beads. Bound proteins were subjected to SDS-PAGE
under reducing conditions, and Western blotting using an antibody against TrkA
20 (C) HMC were incubated with 200 ng/ml rCTGF (FibroGen Inc.) for 2 hours at 4°C. Bound CTGF was cross-linked as above, and a membrane-enriched fraction prepared and solubilised. Cross-linked CTGF-complexes in the solubilised fraction were captured on anti-C-tenninus-CTGF antibody affinity beads (lane 1), or the fraction was 2s incubated with control IgG affinity beads (lane 2). Bound proteins were analysed by Western blotting using anti-TrkA antibody.
(D) The sample shown in lane 1 of Figure 4C, was boiled for a longer time and then Western blotted using anti-TrkA antibody.
(E) Blot (D) was stripped and re-probed using anti-p75NTR antibody.
Results are representative of 4 separate experiments.
s Figure 5 - ~C expresses Trk receptors Total RNA was extracted from I3MC and used for RT-PCR. After amplification, 10 ~.l of each PCR reaction product was electrophoresed through a 1.2% (w/v) agarose gel containing ethidium bromide (0.5 ~.g/ml).
to Results are representative of three separate experiments.
Figure 6 - CTGF activates TrkA in IIIVIC
Serum-starved HMC were incubated in the absence (lane 1) or the presence 15 (lane 2) of CTGF/VS (40 ng/ml) for 15 min. Equal amounts of cellular lysate protein were subjected to SDS-PAGE and analysed by Western blotting. Blot A was probed with anti-TrkA antibody. Blot B was probed with anti-phospho-TrkA. (Tyr490) antibody, while blot C was probed with anti-phospho-TrkA (Tyr674/675). Results are representative of three 2o separate experiments.
Figure 7 - Stimulation of TIED levels by CTGF in I~NdC
Serum-starved HMC were exposed to rCTGF/VS fusion protein for 25 different periods of time, after which cell lysates were prepared and the TIEG and b-actin levels analysed by Western blotting. A representative blot of the three independent experiments (three replicate cultures per condition per experiment) that were performed is shown.
Figure 8 - TIED mediates C'fGF-dependent down-regulation of Stead 7 expression level.
Serum-starved HMC were exposed to the conditions indicated in the figure.
s After 24 h, cell lysates were prepared, and the TIEG, Smad 7, and b-actin levels analysed by Western blotting. A representative blot of the three independent experiments (three replicate cultures per condition per experiment) that were performed is shown.
to EXAMPLES
Exczrnpde 1-Identificcztiosz of CTGF- TrkA itzteraction Materials and Methods Cell cultures antibodies and reagents Primary normal adult human mesangial cells (HMC) (CC-2259, lot 3F1510) to (Biowhittaker, Wokingham, Berkshire, U.K.) were maintained in culture as described previously (Wahab N et al. (1996) Bioclzetn J. 316 pp.985-992).
Confluent post-exponential-phase cultures of HMCs (passage 6-8) were maintained in culture medium containing 10% (v/v) foetal calf serum and 4 is mM (normoglycaemic), 11, 15 or 30 mM (hyperglycaemic) d-glucose for periods of up to 4 weeks. At the end of each week cultures were washed extensively with ' PB S and were used either for RNA extraction or for culture for 24 h in glucose supplemented medium in the absence of serum.
2o Phospho-Akt antibody (P-Ser 472/473/474) (Pharmingen, San Diego; CA, USA), Phospho-Akt (P-Thr 30~) (Sigma, Gillingham, Dorset, UK) and ERKS antibodies (Sigma, Gillingham, Dorset, UK) were used.
Phospho-ERK1/2 pathway sampler, phospho-JNK pathway sampler, 2s phospho P3 8 MA PK pathway sampler, phospho-PKC d, phospho-PKC a, phospho-TrkA (Tyr674/675), phospho-TrkA (Tyr490) antibodies were from New England BioLabs (Hitchen, Herts., UK). Phospho-CaMKII (P-Thr286) antibody was from Promega (Southampton, Hants., UK) and anti-phospho-tyrosine antibody was from Santa Cruz (Autogen Bioclear, Calne, Wilts., 3o UK). Anti-TrkA antibody was obtained from Upstate Biotechnology (Milton Keynes, UK). Anti-TIEG-1 antibody was a gift from Dr. Steven Johnson (Mayo Foundation, Minnesota, USA). K-252a was purchased from Calbiochem (Nottingham, UK). Recombinant CTGF (CTGF/V5 fusion protein) was expressed in transformed HMC and purified from the medium s using Talon metal affinity resin, (Wahab N et al. (2001) Biochern J. 359 pp.77-87). Alternatively, r-CTGF (non-fusion protein) was expressed in the baculovirus system and was a gift from FibroGen Inc. (South San Francisco, CA, USA). Rabbit anti-CTGF (pAb2) and chicken anti-CTGF
(pIgY3) were also supplied by FibroGen Inc.
to Cross linking and membrane preparation Cell layers were washed twice with cold binding buffer (PBS and 0.5°l°
glucose) and incubated with CTGF in binding buffer for 2 h at 4°C.
After 15 incubation, the cell layers were washed five times with cold binding buffer and incubated with 1mM 3,3'-dithiobis(sulfosuccinilmidylpropionate) (DTSSP) or disuccinimidyl suberate (DSS) (Pierce Biotechnology, Tattenhall, Cheshire, UK) in PBS for 30 min at room temperature. The reaction was halted for 15 min at room temperature by the addition of 50 ao mM Tris buffer pH 7.5.
Cell layers were washed with wash buffer (10 mM Tris buffer (pH 7.5), 5mM MgCl, 150 mM NaCI), scraped in an homogenising buffer (10 mM
Tris buffer (pH 7.5), 250 mM Sucrose, 1 mM EDTA, 5 mM MgCI, 150 mM
2s NaCI, and lx protease inhibitor cocktail (Roche Applied Science, Mannheim, Germany), passed through a 25 gauge needle, and homogenised on ice with 30-40 cycles in a Dounce homogeniser.
The homogenate was centrifuged for 10 min at 2500 x g at 4°C. The 3o resulting supernatant was centrifuged for 90 min at 45000 x g at 4°C. The membrane-enriched pellet was solubilised for 1 h in solubilising buffer (10 mM Tris buffer (pH 7.5), 5 mM MgCl, 150 mM NaCI, 1% Triton-X100, 1x protease inhibitor cocktail (Roche, see above)). Soluble~membrane proteins were collected after further centrifugation for 1 hour at 45000 x g at 4°C.
s Where rCTGF/VS fusion protein was used, CTGF-cross linked proteins were either immunoprecipitated with rabbit anti CTGF antibody, or captured on a Pull-Down PolyHis column (Pierce Biotechnology, Tattenhall, Cheshire, UK).
to Where rCTGF was used, CTGF-cross linked proteins were captured on a goat anti-CTGF-C terminal domain-Sepharose immunoaffinity column, using an IgG-Sepharose column as a control (FibroGen Inc.). After extensive washing of the columns with solubilising buffer, bound proteins 1s were solubilised in reducing SDS-PAGE loading buffer, boiled for 5 min and resolved on 4-12% gradient gels by SDS-PAGE. Gels were either stained with Coomassie blue, or were used for Western blotting.
RNA extraction and RT-PCR analysis Total RNA was extracted from 6 x 106 mesangial cells using the RNAzoI B
method (AMS Biotechnology (UK) Ltd., Oxfordshire, UI~). Equal amounts of total RNA (2 ~.g) from each sample were reverse transcribed into cDNAs using Superscript II RNase H+ reverse transcriptase (Gibco BRL, Paisley, 2s Scotland, UK) and random primers.
Equal amounts (0.5 ~l) of the reverse transcription reaction (20 ~l) were subjected to PCR amplification in a 100 ~.l volume containing 10 ~l of 10 x PCR buffer, 16 ~l dNTPs (1.25 mM each), 2 mM MgCl2, 5 M betaine (Sigma), 0.5 ~.M of each specific primer and 1.25 U Amplitaq DNA
polymerase (Gibco BRL). Amplification was started with 5 min of denaturation at 94°C followed by 30 PCR cycles for all genes. Each cycle consisted of 60 s at 94°C, 60 s at SS°C and 60 s at 72°C.
The final extension was for 10 min at 72°C. The sequences of primers to amplify TrkA, TrkB
s and TrkC p75NTR, NGF, BDGF were as described by Anderson et al. (2002) J. Clip. Ehdocf°inol. Metab. 87 pp. 890-897 and shown in Table 1 (adapted from Table I in Anderson et al. (2002)).
to Target Prirraer Sequence 5'-3' TrkA. Forward TCTTCACTGAGTTCCTGGAG
TrkA Reverse TTCTCCACCGGGTCTCCAGA
TrkB Forward AGTCCAGACACTCAGGATTTGTAC
TrkB Reverse CTCCGTGTGATTGGTAACATG
trTrkB Forward CATGTTACCAATCACACGGAGTA
trTrkB Reverse CCATCCAGTGGGATGTTATGAAA
TrkC Forward CATCCATGTGGAATACTACC
TrlcC Reverse TGGGTCACAGTGATAGGAGG
Western blotting Cells were lysed in reducing SDS-PAGE loading buffer and immediately 15 scraped off the plate. Cell lysates were sonicated for 10 seconds to shear the DNA. Samples were then boiled for 5 minutes and resolved on 4-12%
gradient gels by SDS-PAGE. Proteins were transferred onto a polyvinylidene difluoride membrane filter (Immobilin-P, Millipore, Bedford, LTK) using a BioRad transfer apparatus. Blots were incubated in 2o blocking buffer containing 1Y TBS, 0.1% Tween-20 with 5% (wlv) non-fat dry milk, for 1 h.
Immunodetection was performed by incubating the blots in primary antibody at the appropriate dilution in antibody dilution buffer (lx TBS, 0.1% Tween-20 with 5% BSA), overnight at 4°C. Blots were then washed 3 times with washing buffer (1x TBS, 0.1 % Tween-20) and incubated with secondary horseradish peroxidase (HRP)-conjugated antibodies for 1 h at room temperature.
Bound antibodies were visualised using the enhanced chemi-luminescence to reagent Luminol (Autogen Bioclear UI~ Ltd, Wiltshire, UK). Pre-stained molecular weight standards (Amersham International PLC, Amersham, UK) were used to monitor protein migration.
Immunofluorescence staining 1s Cells were fixed with 3.7% paraformaldehyde and permeabilized with 0.5%
Triton X-100 in PBS for 10 min at room- temperature. Coverslips were then incubated overnight at 4°C with serum (5°l° in PBS) from the same species as that in which the secondary antibody was raised. After the first 2o incubation, the coverslips were incubated with primary antibodies (at optimum dilution in PBS containing 3% BSA) for 1 h at 37°C.
The coverslips were then washed and incubated in the dark for 1 h with fluorescein-conjugated secondary antibody (Sigma Aldrich, Dorset, UK).
2s After staining, the coverslips were mounted on glass slides with anti-fade mounting media (Vector Labs, Peterborough, U.K.) and examined using a fluorescence microscope.
~~Sd3~$S
CTGF activates several intracellular si~,nallin~ pathways Purified rCTGF-VS fusion protein was used to identify the intracellular signal pathways which are activated in response to the growth factor in HMC. CTGF was found to rapidly trigger the activation of the classical MAPK (ERKI/2) and JNK pathways (Figures 1A and B) but not the p38 MAPK. Figure 1 shows the maximal activation of these l~inases after 15 min of CTGF stimulation.
CTGF stimulation also led to the activation of Alct, also known as protein kinase B (PKB), at both the known phosphorylation sites; Thr-308 and Ser-fs 473 (Figure 1C). The activation of Thr-308 appears to be rapid and sustained in comparison to the activation of ser- 473.
Activation of Thr-308 is influenced by a phosphoinositide-dependent kinase 1, or PDKl, whose activity is strictly dependent on 3-phosphorylated 2o inositol lipids (Downward J (1998) Curr. Opin. Cell Biol. 10 ppl262-267).
Phosphorylation of Ser-473 is conducted by integrin-linked kinase (ILK) (Attyvell et al. (2000) ~hcogehe 19 pp. 3 811-3 815), and appears to be transient with a maximal level at 15 min, and return to a level close to the basal one within 30 min of CTGF exposure.
CTGF stimulation also led to the transient activation of Cam KII (Figure 1C). ~ther kinases which are activated in response to CTGF are PKC ~ and PKC a (Figure 1D).
CTGF interaction with a receptor Figure 1 demonstrates that CTGF provides a signal to downstream signalling proteins through a receptor that activates the above-mentioned s kinases. These kinases are normally activated by a receptor tyrosine kinase (RTK).
The possibility of CTGF acting through a receptor tyrosine kinase (RTK) was tested by exposing HMC to CTGF for different periods of time. Cell lysates were prepared from the HMC cells and Western Blot analysis performed using an anti-phospho-tyrosine antibody.
The results showed that CTGF fusion protein (40 ng/ml) stimulated tyrosine phosphorylation within 10 min of at least two major proteins with apparent 1s ~MW of about 75-~0 and 140-150 kDa in HMC (Figure 2).
Another phosphotyrosine protein (MW 45 kDa) was detected in control cell lysates but was reduced in response to the CTGF treatment.
2o CTGF interacts with Human Mesangial Cell (HMC) surface proteins The interaction of CTGF with HMC surface proteins was investigated by allowing CTGF to bind to the cell surface. A subsequent cross-linking procedure was performed and a membrane-enriched fraction isolated from 2s the cells. After solubilisation this fraction was immunoprecipitated with a rabbit-anti-CTGF antibody. Covalently linked CTGF complexes were then analysed by PAGE and Western blotting with a chiclcen anti-CTGF
antibody.
In Figure 3, CTGF appears to be cross-linked with membrane proteins to form complexes of apparent molecular weight 85 kDa, 180 kDa and >220 kDa, the latter being a large diffused band (lane 2). These complexes were not immunoprecipitated from the membrane-enriched fraction when the s cross-linking step was eliminated (lane 1).
To ascertain whether CTGF activates an RTK a serum-starved HMC was incubated in both the presence and absence of CTGF for 15 min. The cells were lysed and phospho-tyrosine proteins immunoprecipitated. The to immunoprecipitated proteins were analysed by Western blotting using antibodies against a plurality of known tyrosine kinase receptors.
Figure 4A shows the cross-reacted anti-TrkA antibody (a band of about 140 kDa). The intensity of this band was stronger when cells were iilcubated is with CTGF (lane 2), indicating activation by CTGF.
The interaction of CTGF with the TrkA receptor was confirmed by different experiments in which either His-tagged CTGF/VS fusion protein, or rCTGF
expressed in the baculovirus system, was allowed to bind to the cell surface 2o and then cross-linked to its ligand(s) using the reversible cross-linker DTSSP. The latter is then cleaved by reducing agents.
Subsequently, a membrane fraction was prepared and any cross-linked CTGF complexes were captured on affinity metal beads, or on anti-C-2s terminus CTGF antibody affinity beads. The captured complexes were subjected to SDS-PAGE under reducing conditions and analysed by Western blots.
Figures 4B, 4C, and 4D demonstrate that CTGF interacts with the TrkA
3o receptor.
Trk receptors have previously been shown to interact with the pan neurotrophin receptor p75NTR. Therefore, blots were stripped and re-probed using an anti-p75NTR antibody. Figure 4E shows that the antibody s cross-reacted with a protein of the correct molecular weight for P75NTR.
Thus the results demonstrate that CTGF interacts with the TrkA and p75NTR receptors.
1o HMC ex~aress Trk receptors The expression of Trk receptors by HMC was investigated by extraction of total RNA from HMC for RT-PCR analysis to be performed on. Figure 5 shows that HMC express all three members of the Trk receptor family:
1s TrkA, TrkB, and TrlcC, as well as the pan receptor p75NTR.
CTGF activates TrkA in HMC
TrkA autophosphorylates several tyrosine residues on binding by its ligand, 20 leading to the association and activation of multiple effector molecules.
Phosphorylation at Tyr490 is required for Shc association and activation of the Ras-MAP kinase cascade. Phosphorylations at Tyr674/675 lie within the catalytic domain and reflect Trlc l~inase activity. Therefore we tested whether stimulating cells with CTGF leads to the phosphorylation of TrlcA
2s at these residues. The results in Figure 6 clearly indicate that CTGF
induces the phosphorylation of the receptor at these residues.
Inhibition of CTGF-induced signalling by K252a K252a is an alkaloid-like kinase inhibitor known to selectively inhibit tyrosine l~inases. K252a blocked the protein phosphorylation of ERK1/2, JNK and ERKS in HMC cells stimulated with CTGF. This indicted that the phosphorylation of these kinases is induced by the tyrosine kinase receptor, s trkA, and that a tyrosine kinase inhibitor is capable of inhibiting CTGF
mediated signalling.
CTGF induces expression of TIEG
1o Figure 7 shows that CTGF exposure causes a rapid increase in the expression level of TIEG.
The ability of TIED to directly mediates the CTGF-dependent down-regulation of Smad 7 levels was investigated by treating cells with TIEG
1s antisense and control oligonucleotides. Figure 8 shows that the constitutive levels of both TIEG and Smad 7 proteins in HMC are low (lane 1).
Incubating the cells with CTGF for 24 hours markedly increases the TIEG
level whilst reducing Smad 7 to an almost undetectable level (lane 2). This 2o effect is completely abolished in the presence of TIEG antisense oligonucleotide (lane 5), but not by the control oligonucleotide (lane 6).
Incubating the cells with TGF-b alone for the same period of time led to a moderate increase of both TIEG and Smad 7 (lane 3). However, incubating 2s the cells with TGF-b in the presence of CTGF antisense oligonucleotide completely abolished the moderate induction of TIEG and led to the increased induction of Smad 7 (lane 7). This was not observed in the presence of the control antisense oligonucleotide (lane 8) and is consistent with TGF-b-induced CTGF being responsible for the observed moderate 3o increase in TIEG expression level.
Similar results were also obtained by treating the cells with TIEG antisense and control antisense oligonucleotides (lanes 9 and 10). Incubating the cells with both TGF-b and CTGF (lane 4) marl~edly increases the expression level of TIED whilst reducing the expression level of Smad 7. These results clearly show that TIEG mediates CTGF-dependent down-regulation of Smad 7 expression.
Example 2 - ~S'creening method for identifying compounds i~alzibiting to CTGF induced~brosas Screening for compounds possessing fibrosis inhibitory properties dependent on the CTGF-CTGF receptor interaction is conducted by testing the ability of each compound to bloclc, for example, the induction of TIEG
is in HMC treated with CTGF.
The screening method is conducted using human mesangial cells (HMC) pre-incubated fox 30 minutes with or without the potential inhibitor. These cells are then stimulated with CTGF-VS fusion protein (40 ng/ml) in the 2o presence or absence of the potential inhibitor for 2 hours. After washing the cell layer with cold PBS, the cells are lysed in RIPA buffer and the lysate assayed for TIEG by ELISA.
For the ELISA assay (Voller A et al., (1976) in Manual of Clinical 2s Immunology (Rose, N and Fishman H, eds.) pp 506-512, American Society of Microbiology, Washington, DC.), NUNC microtitre plates axe coated overnight at 4°C with either lysate or with standard dilutions of r-TIEG to provide a standard curve.
After removing the coating solutions and washing the wells briefly with PBS, non-specific proteins are blocked by incubating the wells for 1 hour withl% (w/v) bovine serum albumin in PBS at 37°C. Wells are then incubated with anti-TIEG antibody at optimal dilution for 60 minutes, s followed by peroxidase conjugated secondary antibody for 60 minutes at 37°C. After washing the wells three times with PBS, bound antibody is detected with the substrate 2,2'-azinobis-3-ethylbenzthazoline 6-sulphonic acid and absorbance read at 405 nm.
to Recombinant TIED protein is created from full length TIEG cDNA by cloning into the PcDNA 3.1/VS-His Topo vector (InVitrogen). This vector can be transfected into a mammalian cell line to express TIEG-fusion protein.
Is The TIEG fusion protein is purified from cell lysates using probond nickel=
chelating resin. Anti-TIEG antibody is available from Dr. Steven Johnson (Mayo Foundation, Minnesota, USA) or can be raised in rabbits against the TIEG fusion protein using conventional methods.
2o Example 3 - reducing the development of diabetic nepha opathy ih diabetic mice by bl~cking CTGF ag onist access to cell surface f~eceptors By blocking CTGF agonist access to cell-surface receptors it should be possible to prevent and/or reduce the development of diabetic nephropathy 2s in diabetic mice. This could be done by using an agent that is capable of binding to a CTGF receptor agonist, thereby preventing the agonist from binding to the cell-surface receptors. For example, soluble mouse TrkA
receptor (sTrkA) could be used.
cDNA sequence representing the extracellular region of the CTGF receptors can be generated by RT-PCR, using total RNA extracted from mouse kidneys and specifically-designed oligonucleotide primers. The PCR
product can be cloned in-frame into the pSecTag2 mammalian expression s vector (Invitrogen), designed for efficient secretion of expressed proteins.
It has been shown that the fusion of the Fc portion of immunoglobulin G (IgG) slows the ifz vivo clearance of other soluble receptors (Zhou A, Ueno H, Sbimomura M, Tanalca R, Shirakawa T, Nalcamura H, Matsuo M, Iijima K.
Kidney Int. 2003, 64:92101), so cDNA of the Fc portion of mouse IgG can 1o be amplified by RT-PCR and cloned in-frame with the 3' end of CTGF.
The antisense primer of the mouse Fc should contain a stop-codon to prevent its fusion with the 3~ayc epitope that is present in the pSecTag2 vector. These constructs can be used to generate stably-transfected mouse 1s fibroblast cell lines according to standard techniques, and by using the Zeocin resistant gene present in the pSecTag2 vector for selection.
Cell lines that efficiently express and secrete the receptor can be grown routinely on a large scale (T150 flasks). Expressed recombinant proteins 2o can be purified from media using FPLC Mono S (Pharmacia), and purified proteins can be checked by Coomassie blue-stained SDS-PAGE and dialysed against phosphate-buffered saline (PBS). Dialysed proteins can be passed through Detox-igel columns (Pierce), checlced for endotoxin by using Lilrmlus amebocyte assay (Sigma), and sterile-filtered (0.2~,m).
To test this ifs vivo, four groups of mice can be set up: (a), (b) and (c) db/db mice (n=10 each), and (d) db/m mice (n=10). For these experiments we can use diabetic db/db and non-diabetic db/m mice (Jackson Laboratory). The db/db mouse is a genetically-engineered mouse model that represents type 2 3o diabetes and develops hyperglycaemia associated with obesity and insulin resistance a few weelcs after birth. We would choose this model because it exhibits glomerular mesangial expansion by age 16 weeks (Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP. Cell. 1996, s 84:491-5; Like AA, Lavine RL, Poffenbarger PL, Chick WL. Am J Pathol.
1972, 66:193-224.).
Immediately after onset of diabetes, group (a) will receive daily subcutaneous injections of 50 ~g sTrkA. We would choose this dose on the 1o basis of successful experiments of similar design by other investigators (Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stem D, Schmidt AM. Nat Med. 1998, 4:1025-31; Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Marlcowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, is D'Agati VD, Schmidt AM. Am J Pathol. 2003, 162:1123-37; Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewsl~i C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS. Proc Natl Acad Sci U S
A. 2002, 99:11393-8.).
A subcutaneously injected s-receptor-Fc decoy for VEGF has a serum half life (t1/2) of approximately 2 days. Group (b) should receive equal volumes of vehicle. Group (c) and (d) should receive no treatment. Mice can be sacrificed at 20 weelcs of age to assess the development of diabetic 2s nephropathy.
Development of diabetic nephropathy can be assessed by urine albumin, serum and urine creatinine, changes in the glomerular histology and accumulation of ECM in the glomerulus. Mice should be housed in 3o individual metabolic cages for 24h urine collections. Urinary albumin concentration can be determined with an ELISA using a murine microalbuminuria kit (Albuwell M; Exocell, Philadelphia ). Renal function can be evaluated by calculating creatinine clearance (ml/min/100 g body weight). Serum and urine creatinine levels can be measured by an enzymatic method using the picric acid colorimetric procedure (Sigma).
.Exaa°raple 4 - Pharmaceutical foruaulatioaas aaad adraaifaistration.
The compounds of the invention will normally be administered orally or by to any parenteral route, in the form of a pharmaceutical formulation comprising the active ingredient, optionally in the form of a non-toxic organic, or inorganic, acid, or base, addition salt, in a pharmaceutically acceptable dosage form. Depending upon the disorder and patient to be treated, as well as the route of administration, the compositions may be 1s administered at varying doses.
In human therapy, the compounds of the invention can be administered alone but will generally be administered in admixture with a suitable pharmaceutical excipient diluent or carrier selected with regard to the 2o intended route of administration and standard pharmaceutical practice.
For example, the compounds of the invention can be administered orally, buccally or sublingually in the form of tablets, capsules, ovules, elixixs, solutions or suspensions, which may contain flavouring or colouring agents, 2s for immediate-, delayed- or controlled-release applications. The compounds of invention may also be administered via intracavernosal inj ection.
Such tablets may contain excipients such as microcrystalline cellulose, .;o lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably coin, potato or tapioca starch); sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxy-propylcellulose (HPC), s sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.
Solid compositions of a similar type may also be employed as fillers in 1o gelatin capsules. Preferred excipients in this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the compounds of the invention may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as ~s water, ethanol, propylene glycol and glycerin, and combinations thereof.
The compounds of the invention can also be administered parenterally, for example, intravenously, intra-arterially, intraperitoneally, iiltrathecally, intraventricularly, intrasternally, intracranially, intra-muscularly or 2o subcutaneously, or they may be administered by infusion techniques. They are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable 2s parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.
Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, 3o bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or mufti-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried s (lyophilised) condition requiring only the addition of the sterile liquid carrier, fox example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
1o For oral and parenteral administration to human patients, the daily dosage level of the compounds of the invention will usually be from 1mg/kg to 30 mg/kg. Thus, for example, the tablets or capsules of the compound of the invention may contain a dose of active compound for administration singly or two or more at a time, as appropriate. The physician in any event will 1s determine the actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention.
The compounds of the invention can also be administered intranasally or by inhalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray or nebuliser with the use of a suitable propellant, e.g.
2s dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoro-ethane, a hydrofluoroalkane such as 1,1,1,2-tetrafluoroethane (HFA 134A3 or l,1,1,2,3,3,3-heptafluoropropane (HFA 227EA3), carbon dioxide or other suitable gas. In the case of a pressurised aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurised container, pump, spray or nebuliser may contain a solution or suspension of the active compound, e.g. using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g.
sorbitan trioleate. Capsules and cartridges (made, for example, from s gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
Aerosol or dry powder formulations are preferably arranged so that each 1o metered dose or "puff' delivers an appropriate dose of a compound of the invention for delivery to the patient. It will be appreciated that the overall daily dose with an aerosol will vary from patient to patient, and may be administered in a single dose or, more usually, in divided doses throughout the day.
is Alternatively, the compounds of the invention can be administered in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, cream, ointment or dusting powder. The compounds of the invention may also be transdermally administered, for 2o example, by the use of a slcin patch. They may also be administered by the ocular route, particularly for treating diseases of the eye.
Fox ophthalmic use, the compounds of the invention can be formulated as micronised suspensions in isotonic, pH adjusted, sterile saline, or, 2s preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylallconium chloride.
Alternatively, they may be formulated in an ointment such as petrolatum.
For application topically to the skin, the compounds of the invention can be 3o formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, they can be formulated as a suitable lotion or cream, s suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
to Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouth-washes comprising the active ingredient in a suitable liquid carrier:
is Generally, in humans, oral or topical administration of the compounds of the invention is the preferred route, being the most convenient. In circumstances where the recipient suffers from a swallowing disorder or from impairment of drug absorption after oral administration, the drug may 2o be administered parenterally, e.g. sublingually or buccally.
For veterinary use, a compound of the invention is administered as a suitably acceptable formulation in accordance with normal veterinary practice and the veterinary surgeon will determine the dosing regimen and 2s route of administration which will be most appropriate for a particular animal.
3$
Cell Biol. 19 pp.3811-3815) and it is possible that this interaction is important in mediating some of the cellular phenomena that CTGF induces.
s CTGF is over-expressed in a variety of fibrotic disorders, including diabetic nephropathy (Wahab N et al. (2001) Biochefn J. 359 pp.77-87). In fact, increasing levels of CTGF expression have been shown to correlate with increasing severity and speed of progression of diabetic nephropathy (Ito Y
to et al. (1998) .Kidney hZt. 53 pp.853-886).
Hence, CTGF may be a potentially useful molecular indicator of the fibrotic response. CTGF has not yet been shown to directly induce renal fibrosis in vivo, but, when injected subcutaneously along with TGF-~, induces 1s sustained dermal fibrosis in rats (Mori T et al. (1999) J. Cell. Physiol.
pp 153-159).
In the process of developing this invention, the inventors have demonstrated that CTGF interacts with a cellular receptor, the TrkA receptor, in order to 2o induce intracellular signalling cascades related to the formation of fibrosis.
There axe three Trk receptor tyrosine lcinase genes (TrkA, TrkB and TrkC).
On binding its ligand, the Trk receptor dimerizes and autophosphorylates, leading to the activation of several small G proteins, including Ras, Rap-l, ~s and the Cdc 42-Rac-Rho family, as well as of pathways regulated by MAP
kinase, PI3-kinase, and phospholipase C-y (PLC y) (Segal, 2003). Activated Trk receptors also interact, directly or indirectly, with a variety of cytoplasmic adaptor proteins to produce a number of biological responses including, cell proliferation and survival; axonal and dendritic growth, and remodelling; assembly and remodelling of cytoskeleton; membrane trafficking and fusion; and synapse formation, function, and plasticity (Huang E and Reichardt L, (2003) Afzuu. Rev. Biochem. 72 pp. 609-642).
s The work by the inventors described in the examples, has shown that Trk tyrosine kinase activity is required for the CTGF-dependent induction of intracellular signalling molecules implicated in fibrosis. This work has led to the establishment of a method of identifying and making compounds that can interact with the CTGF receptor and/or an agonist of the CTGF receptor 1o in order to reduce or prevent fibrosis.
Therefore, in a first aspect of the invention is provided a method for identifying and/or making compounds for use in reducing and/or preventing fibrosis, comprising the steps:
(a) providing a CTGF receptor (b) providing a test sample (c) providing a CTGF receptor agonist (d) exposing the CTGF receptor to the test sample (e) subsequently or simultaneously exposing the CTGF receptor to the 2s CTGF receptor agonist (f) detecting and/or measuring the amount of CTGF receptor activation (g) comparing the amount of CTGF receptor activation in the presence of a test sample to the amount of CTGF receptor activation detected and/or measured in the absence of a test sample;
s (h) determining if a compound reduces and/or prevents fibrosis on the basis that it causes no increase or a decrease in CTGF receptor activation.
By "CTGF receptor agonist" we mean a compound acting at the CTGF
receptor to produce an effect that is substantially the same as that of the 1o effect produced by CTGF interacting with the receptor. We also include derivatives, analogues and fragments of CTGF receptor agonists that are capable of producing substantially the same effect as CTGF interacting with the CTGF receptor. CTGF receptor agonists, other than CTGF itself, can be readily identified by measurement and/or detection of CTGF receptor 1s autophosphorylation, receptor induced protein phosphorylation and TIEG
expression using the methods presented in Example 1.
By "derivative" we mean a CTGF receptor agonist compound, additionally having at least one chemical modification of one or more of its amino acid 2o side groups, a-carbon atoms, terminal amino group, or terminal carboxylic acid group. A chemical modification includes adding chemical moieties, creating new bonds, and removing chemical moieties. Modifications at amino acid side groups include acylation of lysine e-amino groups, N-allcylation of arginine, histidine, or lysine, alkylation of glutamic or aspartic 2s carboxylic acid groups, and deamidation of glutamine or asparagine.
Modifications of the terminal amino include the des-amino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications. Modifications of the terminal carboxy group include the amide, lower alkyl amide, dialkyl amide, and lower alkyl ester modifications. A lower alkyl is a C 1 -C4 alkyl.
3o Furthermore, one or more side groups, or terminal groups, may be protected by protective groups l~n.own to the ordinarily spilled protein chemist. The a-carbon of an. amino acid may be mono- or di-methylated.
By "analogue" we mean a CTGF receptor agonist having a modification s including one or more amino acid substitutions, deletions, inversions, or additions and capable of producing an effect that is substantially the same as that of the effect produced by CTGF interacting with the receptor.
By "fragment" we mean a portion of a CTGF receptor agonist capable of 1o producing an effect that is substantially the same as that of the effect produced by CTGF interacting with the receptor.
Optionally the method further comprises the step of isolating the compound which is capable of reducing and/or preventing fibrosis. The isolated 15 compound may then optionally be formulated into a composition further comprising a pharmaceutically acceptable carrier, excipient and/or diluent.
Preferably, CTGF receptor activation is detected and/or measured by detecting andlor measuring at least one of the following activities: CTGF
2o receptor autophosphorylation, CTGF receptor-induced protein phosphorylation or CTGF induced expression of TIEG. Typical methods of measuring these activities are provided in Examples 1 and 2.
Preferably the CTGF receptor agonist is CTGF.
Preferably the CTGF receptor is the TrlcA receptor.
Conveniently the compound affects directly the interaction between the CTGF receptor and an agonist thereof. In other words, the compound interacts directly with the CTGF receptor or agonist thereof in order to reduce the activation of the CTGF receptor.
Alternatively, the compound affects indirectly the interaction between the s CTGF receptor and an agonist thereof. In other words, the compound interacts with the CTGF receptor or agonist thereof indirectly via at least one further compound in order to reduce the activation of the CTGF
receptor.
1o Conveniently, the compound identified and/or made by the method described above is an antagonist of a tyrosine kinase.
By "antagonist" we mean a compound acting at the CTGF receptor to inhibit and/or prevent the effect produced by CTGF or a CTGF receptor 1s agonist interacting with the receptor. We also include derivatives, analogues and fragments of CTGF receptor antagonists that are capable of preventing and/or inhibiting the effect of CTGF and/or a CTGF receptor agonist interacting with the CTGF receptor. CTGF receptor antagonists, can be readily identified by measurement and/or detection of CTGF receptor 2o autophosphorylation, receptor induced protein phosphorylation and TIEG
expression using the methods presented in Example 1.
In a second aspect of the invention there is provided a compound for use in the reduction and/or prevention of fibrosis characterised in that it inhibits 2s and/or prevents CTGF receptor activation; and more preferably inhibits and/or prevents at least one of the following activities: CTGF receptor autophosphorylation; CTGF receptor-induced protein phosphorylation;
and/or induction of TIEG.
Preferably the compound is identified and/or made by the method of the first aspect of the invention.
Conveniently, the compound is at least one selected from polypeptides, antibody molecules and antisense nucleotides. Preferably the compound is an antibody molecule.
The term "antibody molecule" shall be talcen to refer to any one of an antibody, an antibody fragment, or antibody derivative. It is intended to to embrace wildtype antibodies, synthetic antibodies, recombinant antibodies or antibody hybrids, such as, but not limited to, a single-chain modified antibody molecule produced by phage-display of immunoglobulin light and/or heavy chain variable and/or constant regions, or other immunointeractive molecule capable of binding to an antigen in an is immunoassay format that is known to those skilled in the art.
The term "antibody derivative" refers to any modified antibody molecule that is capable of binding to an antigen in an immunoassay format that is known to those skilled in the art, such as a fragment of an antibody (e.g. Fab 20 or Fv fragment), or a modified antibody molecule that is modified by the addition of one or more amino acids or other molecules to facilitate coupling the antibodies to another peptide or polypeptide, to a large carrier protein or to a solid support (e.g. the amino acids tyrosine, lysine, glutamic acid, aspartic acid, cysteine and derivatives thereof, NHZ-acetyl groups or 2s COOH-terminal amido groups, amongst others).
By "antisense oligonucleotides" we mean single-stranded nucleic acids, which can specifically bind to a complementary nucleic acid sequence. By binding to the appropriate target sequence, an RNA-RNA, a DNA-DNA, or 3o RNA-DNA duplex is formed. These nucleic acids are often termed "antisense" because they are complementary to the sense or coding strand of the gene. Recently, formation of a triple helix has proven possible where the oligonucleotide is bound to a DNA duplex. It was found that oligonucleotides could recognise sequences in the major groove of the DNA
s double helix. A triple helix was formed thereby. This suggests that it is possible to synthesise sequence-specific molecules which specifically bind double-stranded DNA via recognition of major groove hydrogen binding sites.
to By binding to the target nucleic acid, the above oligonucleotides can inhibit the function of the target nucleic acid. This could, for example, be a result of blocking the transcription, processing, poly(A)addition, replication, translation, or promoting inhibitory mechanisms of the cells, such as promoting RNA degradations.
Antisense oligonucleotides are prepared in the laboratory and then introduced into cells, for example by microinjection or uptake fiom the cell culture medium into the cells, or they are expressed in cells after transfection with plasmids or retroviruses or other vectors carrying an antisense gene.
Alternatively, the compound is a tyrosine kinase receptor inhibitor.
Preferably the tyrosine kinase inhibitor is selected from the group consisting of BSF-466895, AP-23451, AP-23464, AP-23485, AZD-0530, AP-22408, 2s RG-13022, RG-13291, RG-14620, RP 53801, CEP-075, CEP-2563 dihydrochloride, CHIR-200131, CHIR-258, c jun kinase, I~ST-638, KF-250706, MNAC- .13, anti-EphA2 Mabs, MLN-608, AG-957, lavendustin A
analogues, NSC-330507, NSC-680410, phenylalanine derivatives, SH2 inhibitors, AG-1295, EGF-genistein, erbstatin, genistein, neuT Mab, PPl, 3o TT-232, CGP-52411, CGP-53716, CGP-57148, imatinib, NVP-AAK980-NX, NV-50, phenoxodiol, FAK inhibitors, IGF-1 , Met receptor inhibitors, TIE-2 inhibitors, CP-X64959, PN-355, CP-127374, FCE-26806, FGFR-3 inhibitors, Met RTK antagonists, PD-171026, PD-173956, PD-180970, Src non-RTK antagonists, kahalalide F, CCX2, celastrol, TAK-165 ,TG-100-13, s TG-100-96, desmal, U3-1566 and SKI-606.
Preferably the compound is a CTGF receptor antagonist.
In a third aspect of the invention there is provided a compound of the to second aspect of the invention for use in the treatment and/or prevention and/or diagnosis of a fibrotic disease.
Preferably the compound of the second aspect of the invention is used in the manufacture of a medicament for the treatment and/or prevention and/or is diagnosis of a fibrotic disease.
Conveniently the fibrotic disease is one selected from diabetic nephropathy, non-diabetic kidney fibrosis, lung fibrosis, liver fibrosis (cirrhosis), skeletal muscle fibrosis, cardiac muscle fibrosis, atherosclerosis, systemic sclerosis, 2o scleroderma, retinal fibrosis, radiation fibrosis, keloid scar formation and cancer-associated fibrosis Preferably the disease is diabetic nephropathy.
25 In a fourth aspect of the invention there is provided a method of treating and/or preventing fibrotic disease comprising administering a therapeutically or prophylactically effective dose, or plurality of doses, of a compound identified and/or made according to the method of the first aspect of the invention.
Conveniently the fibrotic disease is one selected from diabetic nephropathy, non-diabetic kidney fibrosis, lung fibrosis, liver fibrosis (cirrhosis), skeletal muscle fibrosis, cardiac muscle fibrosis, atherosclerosis, systemic sclerosis, scleroderma, retinal fibrosis, radiation fibrosis, keloid scar formation and s cancer-associated fibrosis Preferably the disease is diabetic nephropathy.
In a fifth aspect of the invention there is provided a use of an agent capable Io of binding to a CTGF receptor agonist in the treatment and/or prevention and/or diagnosis of a fibrotic disease.
In a sixth aspect of the invention there is provided a use of an agent capable of binding to a CTGF receptor agonist in the manufacture of a medicament 1s for the treatment and/or prevention and/or diagnosis of a fibrotic disease.
Preferably, the fibrotic disease is selected from one or more of diabetic nephropathy, no-diabetic kidney fibrosis, lung fibrosis, liver fibrosis (cirrhosis), skeletal muscle fibrosis, cardiac muscle fibrosis, atherosclerosis, 2o systemic sclerosis, scleroderma, retinal fibrosis, radiation induced fibrosis keloid scar formation and cancer-associated fibrosis.
In a seventh aspect of the invention there is provided a use of an agent capable of binding to a CTGF receptor agonist in a method of reducing 2s and/or preventing binding of a CTGF receptor agonist to a CTGF receptor i~c vivo or ih vita°o.
By "an agent capable of binding to a CTGF receptor agonist" we include a compound, nucleic acid, polypeptide or antibody that is capable of 3o physically associating with a CTGF receptor agonist. Binding between such an agent and a CTGF receptor agonist may occur by ionic, electrostatic and/or covalent interaction. Preferably, the binding of an agent to a CTGF
receptor agonist will reduce and/or prevent the ability of the CTGF receptor agonist to bind to and/or associate with and/or activate a CTGF receptor.
s Preferably, in the seventh aspect of the invention the agent capable of binding to a CTGF receptor agonist is a GTGF receptor. Alternatively, the agent capable of binding to a CTGF receptor agonist is a CTGF receptor joined to the Fc-region of an iinmunoglobulin.
By "Fc-region" we include the "fragment crystallisable" region of an antibody. By "immunoglobulins" we include polypeptides comprising one or more immunoglobulin complementarity-determining region (CDR), such as antibodies, B cell receptors or T cell receptors, or fragments thereof.
Is Preferably, the immunoglobulin is an antibody. More preferably, the immunoglobulin is IgG.
Preferably, in the seventh aspect of the invention there is provided a use wherein the CTGF receptor is the TrkA receptor. Alternatively, the CTGF
2o receptor is a soluble form of the TrkA receptor.
It will be understood that the term "soluble form" includes a form a form of a polypeptide that is not associated with or inserted in the membrane of a cell and which can exist in solution without aggregating.
Preferably, in the fifth, sixth and seventh aspects of the invention the CTGF
agonist is CTGF.
In an eighth aspect of the invention there is provided a nucleic acid encoding the Trl~A receptor joined to an Fc-region of an im~nunoglobulin.
In a ninth aspect of the invention there is provided a vector containing a nucleic acid according to the eighth aspect of the invention.
s In a tenth aspect of the invention there is provided a polypeptide comprising the TrkA receptor joined to an Fc-region of an immunoglobulin.
In an eleventh aspect of the invention there is provided a cell containing a nucleic acid according to the eighth aspect of the invention and/or a vector to according to the ninth aspect of the invention and/or a polypeptide according to the tenth aspect of the invention.
In a twelfth aspect of the invention there is provided a pharmaceutical composition comprising a nucleic acid according to the eighth aspect of the 1s invention and/or a vector according to the ninth aspect of the invention and/or a polypeptide according to the tenth aspect of the invention and/or a cell according to the eleventh aspect of the invention, and a pharmaceutically acceptable carrier or exipient, the nucleic acid and/or the vector and/or the polypeptide and/or the cell being present in an effective 2o amount to treat and/or prevent and/or diagnose a fibrotic disease.
By "effective amount" we include an amount that is sufficient to treat and/or prevent and/or diagnose a fibrotic disease. An effective amount may be determined by use of methods known to those in the art.
Examples embodying certain preferred aspects of the invention will now be described with reference to the following figures in which:-Figure 1 - CTGF activates intracellular signalling pathways Serum-starved human mesangial cells (HMC) incubated in the presence of CTGF/VS fusion protein for the periods of time indicated. Equal amounts of cellular lysate protein were subjected to SDS=PAGE and analysed by Western blotting using phospho-specific antibodies against the constituent s proteins of (A) the MAPK pathway, (B) JNK, and (C) PKB and CamKII. (3-actin is shown as a marker for equal protein loading. D) Cells were grown on coverslips and serum-starved for 48 hours prior to incubation in medium in the absence (a) and (c), or presence of 40 ng/ml CTGF-fusion protein (b) and (d) for 30 min. Cells were fixed, permeabilized, probed with anti-1o phospho PKC 8 (a) and (b) and PKC a (c) and (d) primary antibodies, and then with fiuorescein-conjugated secondary antibody. Results are representative of three separate experiments.
Figure 2 - CTGF induces tyrosine phosphorylation of different proteins 1s Serum-starved HMC were incubated in the presence of 40 ng/ml CTGF/VS
fusion protein for the periods of time indicated. Equal amounts of cellular lysate protein were subjected to SDS-PAGE and analysed by Western blotting using anti-phosphotyrosine antibody. Results are representative of 2o three separate experiments.
Figure 3 - CTGF interacts with I~MfC surface proteins CTGF/VS fusion protein was allowed to bind to the cell surface, and then 25 chemically cross-linked to its ligands with BS3, after which a membrane-enriched fraction was prepared from the cells. Cross-linked CTGF
complexes were immunoprecipitated using rabbit anti-CTGF antibody, resolved by SDS-PAGE, and analysed by Western blotting using chiclcen anti-CTGF antibody (lane 2). The cross-linking step was omitted for some 3o cultures (lane 1). Results are representative of three sepaxate experiments.
Figure 4 - CTGJF interacts with TrkA and p75NTR in IBC
(A) Serum-starved HMC were incubated in the absence (lane 1) or presence s (lane 2) of CTGF/VS fusion protein (40 ng/ml) for 15 min, after which cell lysates were prepared in RIPA buffer. Equal amounts of lysate protein were immunoprecipitated using anti-phosphotyrosine beads.
Bound proteins were resolved by SDS-PAGE and analysed by Western blotting using an antibody against TrkA.
to (B) HMC were incubated in the absence (lane 1) or presence (lane 2) of His tagged-CTGF/VS fusion protein (200 ng/ml) for 2 h at 4°C to allow binding to cell surface receptors, after which the protein was chemically cross-linked with DTSSP. A membrane-enriched fraction was prepared 1s and solubilised. Equal amounts of solubilised protein were incubated with metal affinity beads. Bound proteins were subjected to SDS-PAGE
under reducing conditions, and Western blotting using an antibody against TrkA
20 (C) HMC were incubated with 200 ng/ml rCTGF (FibroGen Inc.) for 2 hours at 4°C. Bound CTGF was cross-linked as above, and a membrane-enriched fraction prepared and solubilised. Cross-linked CTGF-complexes in the solubilised fraction were captured on anti-C-tenninus-CTGF antibody affinity beads (lane 1), or the fraction was 2s incubated with control IgG affinity beads (lane 2). Bound proteins were analysed by Western blotting using anti-TrkA antibody.
(D) The sample shown in lane 1 of Figure 4C, was boiled for a longer time and then Western blotted using anti-TrkA antibody.
(E) Blot (D) was stripped and re-probed using anti-p75NTR antibody.
Results are representative of 4 separate experiments.
s Figure 5 - ~C expresses Trk receptors Total RNA was extracted from I3MC and used for RT-PCR. After amplification, 10 ~.l of each PCR reaction product was electrophoresed through a 1.2% (w/v) agarose gel containing ethidium bromide (0.5 ~.g/ml).
to Results are representative of three separate experiments.
Figure 6 - CTGF activates TrkA in IIIVIC
Serum-starved HMC were incubated in the absence (lane 1) or the presence 15 (lane 2) of CTGF/VS (40 ng/ml) for 15 min. Equal amounts of cellular lysate protein were subjected to SDS-PAGE and analysed by Western blotting. Blot A was probed with anti-TrkA antibody. Blot B was probed with anti-phospho-TrkA. (Tyr490) antibody, while blot C was probed with anti-phospho-TrkA (Tyr674/675). Results are representative of three 2o separate experiments.
Figure 7 - Stimulation of TIED levels by CTGF in I~NdC
Serum-starved HMC were exposed to rCTGF/VS fusion protein for 25 different periods of time, after which cell lysates were prepared and the TIEG and b-actin levels analysed by Western blotting. A representative blot of the three independent experiments (three replicate cultures per condition per experiment) that were performed is shown.
Figure 8 - TIED mediates C'fGF-dependent down-regulation of Stead 7 expression level.
Serum-starved HMC were exposed to the conditions indicated in the figure.
s After 24 h, cell lysates were prepared, and the TIEG, Smad 7, and b-actin levels analysed by Western blotting. A representative blot of the three independent experiments (three replicate cultures per condition per experiment) that were performed is shown.
to EXAMPLES
Exczrnpde 1-Identificcztiosz of CTGF- TrkA itzteraction Materials and Methods Cell cultures antibodies and reagents Primary normal adult human mesangial cells (HMC) (CC-2259, lot 3F1510) to (Biowhittaker, Wokingham, Berkshire, U.K.) were maintained in culture as described previously (Wahab N et al. (1996) Bioclzetn J. 316 pp.985-992).
Confluent post-exponential-phase cultures of HMCs (passage 6-8) were maintained in culture medium containing 10% (v/v) foetal calf serum and 4 is mM (normoglycaemic), 11, 15 or 30 mM (hyperglycaemic) d-glucose for periods of up to 4 weeks. At the end of each week cultures were washed extensively with ' PB S and were used either for RNA extraction or for culture for 24 h in glucose supplemented medium in the absence of serum.
2o Phospho-Akt antibody (P-Ser 472/473/474) (Pharmingen, San Diego; CA, USA), Phospho-Akt (P-Thr 30~) (Sigma, Gillingham, Dorset, UK) and ERKS antibodies (Sigma, Gillingham, Dorset, UK) were used.
Phospho-ERK1/2 pathway sampler, phospho-JNK pathway sampler, 2s phospho P3 8 MA PK pathway sampler, phospho-PKC d, phospho-PKC a, phospho-TrkA (Tyr674/675), phospho-TrkA (Tyr490) antibodies were from New England BioLabs (Hitchen, Herts., UK). Phospho-CaMKII (P-Thr286) antibody was from Promega (Southampton, Hants., UK) and anti-phospho-tyrosine antibody was from Santa Cruz (Autogen Bioclear, Calne, Wilts., 3o UK). Anti-TrkA antibody was obtained from Upstate Biotechnology (Milton Keynes, UK). Anti-TIEG-1 antibody was a gift from Dr. Steven Johnson (Mayo Foundation, Minnesota, USA). K-252a was purchased from Calbiochem (Nottingham, UK). Recombinant CTGF (CTGF/V5 fusion protein) was expressed in transformed HMC and purified from the medium s using Talon metal affinity resin, (Wahab N et al. (2001) Biochern J. 359 pp.77-87). Alternatively, r-CTGF (non-fusion protein) was expressed in the baculovirus system and was a gift from FibroGen Inc. (South San Francisco, CA, USA). Rabbit anti-CTGF (pAb2) and chicken anti-CTGF
(pIgY3) were also supplied by FibroGen Inc.
to Cross linking and membrane preparation Cell layers were washed twice with cold binding buffer (PBS and 0.5°l°
glucose) and incubated with CTGF in binding buffer for 2 h at 4°C.
After 15 incubation, the cell layers were washed five times with cold binding buffer and incubated with 1mM 3,3'-dithiobis(sulfosuccinilmidylpropionate) (DTSSP) or disuccinimidyl suberate (DSS) (Pierce Biotechnology, Tattenhall, Cheshire, UK) in PBS for 30 min at room temperature. The reaction was halted for 15 min at room temperature by the addition of 50 ao mM Tris buffer pH 7.5.
Cell layers were washed with wash buffer (10 mM Tris buffer (pH 7.5), 5mM MgCl, 150 mM NaCI), scraped in an homogenising buffer (10 mM
Tris buffer (pH 7.5), 250 mM Sucrose, 1 mM EDTA, 5 mM MgCI, 150 mM
2s NaCI, and lx protease inhibitor cocktail (Roche Applied Science, Mannheim, Germany), passed through a 25 gauge needle, and homogenised on ice with 30-40 cycles in a Dounce homogeniser.
The homogenate was centrifuged for 10 min at 2500 x g at 4°C. The 3o resulting supernatant was centrifuged for 90 min at 45000 x g at 4°C. The membrane-enriched pellet was solubilised for 1 h in solubilising buffer (10 mM Tris buffer (pH 7.5), 5 mM MgCl, 150 mM NaCI, 1% Triton-X100, 1x protease inhibitor cocktail (Roche, see above)). Soluble~membrane proteins were collected after further centrifugation for 1 hour at 45000 x g at 4°C.
s Where rCTGF/VS fusion protein was used, CTGF-cross linked proteins were either immunoprecipitated with rabbit anti CTGF antibody, or captured on a Pull-Down PolyHis column (Pierce Biotechnology, Tattenhall, Cheshire, UK).
to Where rCTGF was used, CTGF-cross linked proteins were captured on a goat anti-CTGF-C terminal domain-Sepharose immunoaffinity column, using an IgG-Sepharose column as a control (FibroGen Inc.). After extensive washing of the columns with solubilising buffer, bound proteins 1s were solubilised in reducing SDS-PAGE loading buffer, boiled for 5 min and resolved on 4-12% gradient gels by SDS-PAGE. Gels were either stained with Coomassie blue, or were used for Western blotting.
RNA extraction and RT-PCR analysis Total RNA was extracted from 6 x 106 mesangial cells using the RNAzoI B
method (AMS Biotechnology (UK) Ltd., Oxfordshire, UI~). Equal amounts of total RNA (2 ~.g) from each sample were reverse transcribed into cDNAs using Superscript II RNase H+ reverse transcriptase (Gibco BRL, Paisley, 2s Scotland, UK) and random primers.
Equal amounts (0.5 ~l) of the reverse transcription reaction (20 ~l) were subjected to PCR amplification in a 100 ~.l volume containing 10 ~l of 10 x PCR buffer, 16 ~l dNTPs (1.25 mM each), 2 mM MgCl2, 5 M betaine (Sigma), 0.5 ~.M of each specific primer and 1.25 U Amplitaq DNA
polymerase (Gibco BRL). Amplification was started with 5 min of denaturation at 94°C followed by 30 PCR cycles for all genes. Each cycle consisted of 60 s at 94°C, 60 s at SS°C and 60 s at 72°C.
The final extension was for 10 min at 72°C. The sequences of primers to amplify TrkA, TrkB
s and TrkC p75NTR, NGF, BDGF were as described by Anderson et al. (2002) J. Clip. Ehdocf°inol. Metab. 87 pp. 890-897 and shown in Table 1 (adapted from Table I in Anderson et al. (2002)).
to Target Prirraer Sequence 5'-3' TrkA. Forward TCTTCACTGAGTTCCTGGAG
TrkA Reverse TTCTCCACCGGGTCTCCAGA
TrkB Forward AGTCCAGACACTCAGGATTTGTAC
TrkB Reverse CTCCGTGTGATTGGTAACATG
trTrkB Forward CATGTTACCAATCACACGGAGTA
trTrkB Reverse CCATCCAGTGGGATGTTATGAAA
TrkC Forward CATCCATGTGGAATACTACC
TrlcC Reverse TGGGTCACAGTGATAGGAGG
Western blotting Cells were lysed in reducing SDS-PAGE loading buffer and immediately 15 scraped off the plate. Cell lysates were sonicated for 10 seconds to shear the DNA. Samples were then boiled for 5 minutes and resolved on 4-12%
gradient gels by SDS-PAGE. Proteins were transferred onto a polyvinylidene difluoride membrane filter (Immobilin-P, Millipore, Bedford, LTK) using a BioRad transfer apparatus. Blots were incubated in 2o blocking buffer containing 1Y TBS, 0.1% Tween-20 with 5% (wlv) non-fat dry milk, for 1 h.
Immunodetection was performed by incubating the blots in primary antibody at the appropriate dilution in antibody dilution buffer (lx TBS, 0.1% Tween-20 with 5% BSA), overnight at 4°C. Blots were then washed 3 times with washing buffer (1x TBS, 0.1 % Tween-20) and incubated with secondary horseradish peroxidase (HRP)-conjugated antibodies for 1 h at room temperature.
Bound antibodies were visualised using the enhanced chemi-luminescence to reagent Luminol (Autogen Bioclear UI~ Ltd, Wiltshire, UK). Pre-stained molecular weight standards (Amersham International PLC, Amersham, UK) were used to monitor protein migration.
Immunofluorescence staining 1s Cells were fixed with 3.7% paraformaldehyde and permeabilized with 0.5%
Triton X-100 in PBS for 10 min at room- temperature. Coverslips were then incubated overnight at 4°C with serum (5°l° in PBS) from the same species as that in which the secondary antibody was raised. After the first 2o incubation, the coverslips were incubated with primary antibodies (at optimum dilution in PBS containing 3% BSA) for 1 h at 37°C.
The coverslips were then washed and incubated in the dark for 1 h with fluorescein-conjugated secondary antibody (Sigma Aldrich, Dorset, UK).
2s After staining, the coverslips were mounted on glass slides with anti-fade mounting media (Vector Labs, Peterborough, U.K.) and examined using a fluorescence microscope.
~~Sd3~$S
CTGF activates several intracellular si~,nallin~ pathways Purified rCTGF-VS fusion protein was used to identify the intracellular signal pathways which are activated in response to the growth factor in HMC. CTGF was found to rapidly trigger the activation of the classical MAPK (ERKI/2) and JNK pathways (Figures 1A and B) but not the p38 MAPK. Figure 1 shows the maximal activation of these l~inases after 15 min of CTGF stimulation.
CTGF stimulation also led to the activation of Alct, also known as protein kinase B (PKB), at both the known phosphorylation sites; Thr-308 and Ser-fs 473 (Figure 1C). The activation of Thr-308 appears to be rapid and sustained in comparison to the activation of ser- 473.
Activation of Thr-308 is influenced by a phosphoinositide-dependent kinase 1, or PDKl, whose activity is strictly dependent on 3-phosphorylated 2o inositol lipids (Downward J (1998) Curr. Opin. Cell Biol. 10 ppl262-267).
Phosphorylation of Ser-473 is conducted by integrin-linked kinase (ILK) (Attyvell et al. (2000) ~hcogehe 19 pp. 3 811-3 815), and appears to be transient with a maximal level at 15 min, and return to a level close to the basal one within 30 min of CTGF exposure.
CTGF stimulation also led to the transient activation of Cam KII (Figure 1C). ~ther kinases which are activated in response to CTGF are PKC ~ and PKC a (Figure 1D).
CTGF interaction with a receptor Figure 1 demonstrates that CTGF provides a signal to downstream signalling proteins through a receptor that activates the above-mentioned s kinases. These kinases are normally activated by a receptor tyrosine kinase (RTK).
The possibility of CTGF acting through a receptor tyrosine kinase (RTK) was tested by exposing HMC to CTGF for different periods of time. Cell lysates were prepared from the HMC cells and Western Blot analysis performed using an anti-phospho-tyrosine antibody.
The results showed that CTGF fusion protein (40 ng/ml) stimulated tyrosine phosphorylation within 10 min of at least two major proteins with apparent 1s ~MW of about 75-~0 and 140-150 kDa in HMC (Figure 2).
Another phosphotyrosine protein (MW 45 kDa) was detected in control cell lysates but was reduced in response to the CTGF treatment.
2o CTGF interacts with Human Mesangial Cell (HMC) surface proteins The interaction of CTGF with HMC surface proteins was investigated by allowing CTGF to bind to the cell surface. A subsequent cross-linking procedure was performed and a membrane-enriched fraction isolated from 2s the cells. After solubilisation this fraction was immunoprecipitated with a rabbit-anti-CTGF antibody. Covalently linked CTGF complexes were then analysed by PAGE and Western blotting with a chiclcen anti-CTGF
antibody.
In Figure 3, CTGF appears to be cross-linked with membrane proteins to form complexes of apparent molecular weight 85 kDa, 180 kDa and >220 kDa, the latter being a large diffused band (lane 2). These complexes were not immunoprecipitated from the membrane-enriched fraction when the s cross-linking step was eliminated (lane 1).
To ascertain whether CTGF activates an RTK a serum-starved HMC was incubated in both the presence and absence of CTGF for 15 min. The cells were lysed and phospho-tyrosine proteins immunoprecipitated. The to immunoprecipitated proteins were analysed by Western blotting using antibodies against a plurality of known tyrosine kinase receptors.
Figure 4A shows the cross-reacted anti-TrkA antibody (a band of about 140 kDa). The intensity of this band was stronger when cells were iilcubated is with CTGF (lane 2), indicating activation by CTGF.
The interaction of CTGF with the TrkA receptor was confirmed by different experiments in which either His-tagged CTGF/VS fusion protein, or rCTGF
expressed in the baculovirus system, was allowed to bind to the cell surface 2o and then cross-linked to its ligand(s) using the reversible cross-linker DTSSP. The latter is then cleaved by reducing agents.
Subsequently, a membrane fraction was prepared and any cross-linked CTGF complexes were captured on affinity metal beads, or on anti-C-2s terminus CTGF antibody affinity beads. The captured complexes were subjected to SDS-PAGE under reducing conditions and analysed by Western blots.
Figures 4B, 4C, and 4D demonstrate that CTGF interacts with the TrkA
3o receptor.
Trk receptors have previously been shown to interact with the pan neurotrophin receptor p75NTR. Therefore, blots were stripped and re-probed using an anti-p75NTR antibody. Figure 4E shows that the antibody s cross-reacted with a protein of the correct molecular weight for P75NTR.
Thus the results demonstrate that CTGF interacts with the TrkA and p75NTR receptors.
1o HMC ex~aress Trk receptors The expression of Trk receptors by HMC was investigated by extraction of total RNA from HMC for RT-PCR analysis to be performed on. Figure 5 shows that HMC express all three members of the Trk receptor family:
1s TrkA, TrkB, and TrlcC, as well as the pan receptor p75NTR.
CTGF activates TrkA in HMC
TrkA autophosphorylates several tyrosine residues on binding by its ligand, 20 leading to the association and activation of multiple effector molecules.
Phosphorylation at Tyr490 is required for Shc association and activation of the Ras-MAP kinase cascade. Phosphorylations at Tyr674/675 lie within the catalytic domain and reflect Trlc l~inase activity. Therefore we tested whether stimulating cells with CTGF leads to the phosphorylation of TrlcA
2s at these residues. The results in Figure 6 clearly indicate that CTGF
induces the phosphorylation of the receptor at these residues.
Inhibition of CTGF-induced signalling by K252a K252a is an alkaloid-like kinase inhibitor known to selectively inhibit tyrosine l~inases. K252a blocked the protein phosphorylation of ERK1/2, JNK and ERKS in HMC cells stimulated with CTGF. This indicted that the phosphorylation of these kinases is induced by the tyrosine kinase receptor, s trkA, and that a tyrosine kinase inhibitor is capable of inhibiting CTGF
mediated signalling.
CTGF induces expression of TIEG
1o Figure 7 shows that CTGF exposure causes a rapid increase in the expression level of TIEG.
The ability of TIED to directly mediates the CTGF-dependent down-regulation of Smad 7 levels was investigated by treating cells with TIEG
1s antisense and control oligonucleotides. Figure 8 shows that the constitutive levels of both TIEG and Smad 7 proteins in HMC are low (lane 1).
Incubating the cells with CTGF for 24 hours markedly increases the TIEG
level whilst reducing Smad 7 to an almost undetectable level (lane 2). This 2o effect is completely abolished in the presence of TIEG antisense oligonucleotide (lane 5), but not by the control oligonucleotide (lane 6).
Incubating the cells with TGF-b alone for the same period of time led to a moderate increase of both TIEG and Smad 7 (lane 3). However, incubating 2s the cells with TGF-b in the presence of CTGF antisense oligonucleotide completely abolished the moderate induction of TIEG and led to the increased induction of Smad 7 (lane 7). This was not observed in the presence of the control antisense oligonucleotide (lane 8) and is consistent with TGF-b-induced CTGF being responsible for the observed moderate 3o increase in TIEG expression level.
Similar results were also obtained by treating the cells with TIEG antisense and control antisense oligonucleotides (lanes 9 and 10). Incubating the cells with both TGF-b and CTGF (lane 4) marl~edly increases the expression level of TIED whilst reducing the expression level of Smad 7. These results clearly show that TIEG mediates CTGF-dependent down-regulation of Smad 7 expression.
Example 2 - ~S'creening method for identifying compounds i~alzibiting to CTGF induced~brosas Screening for compounds possessing fibrosis inhibitory properties dependent on the CTGF-CTGF receptor interaction is conducted by testing the ability of each compound to bloclc, for example, the induction of TIEG
is in HMC treated with CTGF.
The screening method is conducted using human mesangial cells (HMC) pre-incubated fox 30 minutes with or without the potential inhibitor. These cells are then stimulated with CTGF-VS fusion protein (40 ng/ml) in the 2o presence or absence of the potential inhibitor for 2 hours. After washing the cell layer with cold PBS, the cells are lysed in RIPA buffer and the lysate assayed for TIEG by ELISA.
For the ELISA assay (Voller A et al., (1976) in Manual of Clinical 2s Immunology (Rose, N and Fishman H, eds.) pp 506-512, American Society of Microbiology, Washington, DC.), NUNC microtitre plates axe coated overnight at 4°C with either lysate or with standard dilutions of r-TIEG to provide a standard curve.
After removing the coating solutions and washing the wells briefly with PBS, non-specific proteins are blocked by incubating the wells for 1 hour withl% (w/v) bovine serum albumin in PBS at 37°C. Wells are then incubated with anti-TIEG antibody at optimal dilution for 60 minutes, s followed by peroxidase conjugated secondary antibody for 60 minutes at 37°C. After washing the wells three times with PBS, bound antibody is detected with the substrate 2,2'-azinobis-3-ethylbenzthazoline 6-sulphonic acid and absorbance read at 405 nm.
to Recombinant TIED protein is created from full length TIEG cDNA by cloning into the PcDNA 3.1/VS-His Topo vector (InVitrogen). This vector can be transfected into a mammalian cell line to express TIEG-fusion protein.
Is The TIEG fusion protein is purified from cell lysates using probond nickel=
chelating resin. Anti-TIEG antibody is available from Dr. Steven Johnson (Mayo Foundation, Minnesota, USA) or can be raised in rabbits against the TIEG fusion protein using conventional methods.
2o Example 3 - reducing the development of diabetic nepha opathy ih diabetic mice by bl~cking CTGF ag onist access to cell surface f~eceptors By blocking CTGF agonist access to cell-surface receptors it should be possible to prevent and/or reduce the development of diabetic nephropathy 2s in diabetic mice. This could be done by using an agent that is capable of binding to a CTGF receptor agonist, thereby preventing the agonist from binding to the cell-surface receptors. For example, soluble mouse TrkA
receptor (sTrkA) could be used.
cDNA sequence representing the extracellular region of the CTGF receptors can be generated by RT-PCR, using total RNA extracted from mouse kidneys and specifically-designed oligonucleotide primers. The PCR
product can be cloned in-frame into the pSecTag2 mammalian expression s vector (Invitrogen), designed for efficient secretion of expressed proteins.
It has been shown that the fusion of the Fc portion of immunoglobulin G (IgG) slows the ifz vivo clearance of other soluble receptors (Zhou A, Ueno H, Sbimomura M, Tanalca R, Shirakawa T, Nalcamura H, Matsuo M, Iijima K.
Kidney Int. 2003, 64:92101), so cDNA of the Fc portion of mouse IgG can 1o be amplified by RT-PCR and cloned in-frame with the 3' end of CTGF.
The antisense primer of the mouse Fc should contain a stop-codon to prevent its fusion with the 3~ayc epitope that is present in the pSecTag2 vector. These constructs can be used to generate stably-transfected mouse 1s fibroblast cell lines according to standard techniques, and by using the Zeocin resistant gene present in the pSecTag2 vector for selection.
Cell lines that efficiently express and secrete the receptor can be grown routinely on a large scale (T150 flasks). Expressed recombinant proteins 2o can be purified from media using FPLC Mono S (Pharmacia), and purified proteins can be checked by Coomassie blue-stained SDS-PAGE and dialysed against phosphate-buffered saline (PBS). Dialysed proteins can be passed through Detox-igel columns (Pierce), checlced for endotoxin by using Lilrmlus amebocyte assay (Sigma), and sterile-filtered (0.2~,m).
To test this ifs vivo, four groups of mice can be set up: (a), (b) and (c) db/db mice (n=10 each), and (d) db/m mice (n=10). For these experiments we can use diabetic db/db and non-diabetic db/m mice (Jackson Laboratory). The db/db mouse is a genetically-engineered mouse model that represents type 2 3o diabetes and develops hyperglycaemia associated with obesity and insulin resistance a few weelcs after birth. We would choose this model because it exhibits glomerular mesangial expansion by age 16 weeks (Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP. Cell. 1996, s 84:491-5; Like AA, Lavine RL, Poffenbarger PL, Chick WL. Am J Pathol.
1972, 66:193-224.).
Immediately after onset of diabetes, group (a) will receive daily subcutaneous injections of 50 ~g sTrkA. We would choose this dose on the 1o basis of successful experiments of similar design by other investigators (Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stem D, Schmidt AM. Nat Med. 1998, 4:1025-31; Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Marlcowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, is D'Agati VD, Schmidt AM. Am J Pathol. 2003, 162:1123-37; Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewsl~i C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS. Proc Natl Acad Sci U S
A. 2002, 99:11393-8.).
A subcutaneously injected s-receptor-Fc decoy for VEGF has a serum half life (t1/2) of approximately 2 days. Group (b) should receive equal volumes of vehicle. Group (c) and (d) should receive no treatment. Mice can be sacrificed at 20 weelcs of age to assess the development of diabetic 2s nephropathy.
Development of diabetic nephropathy can be assessed by urine albumin, serum and urine creatinine, changes in the glomerular histology and accumulation of ECM in the glomerulus. Mice should be housed in 3o individual metabolic cages for 24h urine collections. Urinary albumin concentration can be determined with an ELISA using a murine microalbuminuria kit (Albuwell M; Exocell, Philadelphia ). Renal function can be evaluated by calculating creatinine clearance (ml/min/100 g body weight). Serum and urine creatinine levels can be measured by an enzymatic method using the picric acid colorimetric procedure (Sigma).
.Exaa°raple 4 - Pharmaceutical foruaulatioaas aaad adraaifaistration.
The compounds of the invention will normally be administered orally or by to any parenteral route, in the form of a pharmaceutical formulation comprising the active ingredient, optionally in the form of a non-toxic organic, or inorganic, acid, or base, addition salt, in a pharmaceutically acceptable dosage form. Depending upon the disorder and patient to be treated, as well as the route of administration, the compositions may be 1s administered at varying doses.
In human therapy, the compounds of the invention can be administered alone but will generally be administered in admixture with a suitable pharmaceutical excipient diluent or carrier selected with regard to the 2o intended route of administration and standard pharmaceutical practice.
For example, the compounds of the invention can be administered orally, buccally or sublingually in the form of tablets, capsules, ovules, elixixs, solutions or suspensions, which may contain flavouring or colouring agents, 2s for immediate-, delayed- or controlled-release applications. The compounds of invention may also be administered via intracavernosal inj ection.
Such tablets may contain excipients such as microcrystalline cellulose, .;o lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably coin, potato or tapioca starch); sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxy-propylcellulose (HPC), s sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.
Solid compositions of a similar type may also be employed as fillers in 1o gelatin capsules. Preferred excipients in this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the compounds of the invention may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as ~s water, ethanol, propylene glycol and glycerin, and combinations thereof.
The compounds of the invention can also be administered parenterally, for example, intravenously, intra-arterially, intraperitoneally, iiltrathecally, intraventricularly, intrasternally, intracranially, intra-muscularly or 2o subcutaneously, or they may be administered by infusion techniques. They are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable 2s parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.
Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, 3o bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or mufti-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried s (lyophilised) condition requiring only the addition of the sterile liquid carrier, fox example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
1o For oral and parenteral administration to human patients, the daily dosage level of the compounds of the invention will usually be from 1mg/kg to 30 mg/kg. Thus, for example, the tablets or capsules of the compound of the invention may contain a dose of active compound for administration singly or two or more at a time, as appropriate. The physician in any event will 1s determine the actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention.
The compounds of the invention can also be administered intranasally or by inhalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray or nebuliser with the use of a suitable propellant, e.g.
2s dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoro-ethane, a hydrofluoroalkane such as 1,1,1,2-tetrafluoroethane (HFA 134A3 or l,1,1,2,3,3,3-heptafluoropropane (HFA 227EA3), carbon dioxide or other suitable gas. In the case of a pressurised aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurised container, pump, spray or nebuliser may contain a solution or suspension of the active compound, e.g. using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g.
sorbitan trioleate. Capsules and cartridges (made, for example, from s gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
Aerosol or dry powder formulations are preferably arranged so that each 1o metered dose or "puff' delivers an appropriate dose of a compound of the invention for delivery to the patient. It will be appreciated that the overall daily dose with an aerosol will vary from patient to patient, and may be administered in a single dose or, more usually, in divided doses throughout the day.
is Alternatively, the compounds of the invention can be administered in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, cream, ointment or dusting powder. The compounds of the invention may also be transdermally administered, for 2o example, by the use of a slcin patch. They may also be administered by the ocular route, particularly for treating diseases of the eye.
Fox ophthalmic use, the compounds of the invention can be formulated as micronised suspensions in isotonic, pH adjusted, sterile saline, or, 2s preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylallconium chloride.
Alternatively, they may be formulated in an ointment such as petrolatum.
For application topically to the skin, the compounds of the invention can be 3o formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, they can be formulated as a suitable lotion or cream, s suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
to Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouth-washes comprising the active ingredient in a suitable liquid carrier:
is Generally, in humans, oral or topical administration of the compounds of the invention is the preferred route, being the most convenient. In circumstances where the recipient suffers from a swallowing disorder or from impairment of drug absorption after oral administration, the drug may 2o be administered parenterally, e.g. sublingually or buccally.
For veterinary use, a compound of the invention is administered as a suitably acceptable formulation in accordance with normal veterinary practice and the veterinary surgeon will determine the dosing regimen and 2s route of administration which will be most appropriate for a particular animal.
3$
Claims (37)
1. A method for identifying and/or making compounds for use in reducing and/or preventing fibrosis, comprising the steps:
(a) providing a CTGF receptor;
(b) providing a test sample;
(c) providing a CTGF receptor agonist;
(d) exposing the CTGF receptor to the test sample;
(e) subsequently or simultaneously exposing the CTGF receptor to the CTGF receptor agonist;
(f) detecting and/or measuring the amount of CTGF receptor activation;
(g) comparing the amount of CTGF receptor activation in the presence of a test sample with the amount of CTGF receptor activation detected and/or measured in the absence of a test sample; and (h) determining if a compound reduces and/or prevents fibrosis on the basis that it causes no increase or a decrease in CTGF
receptor activation.
(a) providing a CTGF receptor;
(b) providing a test sample;
(c) providing a CTGF receptor agonist;
(d) exposing the CTGF receptor to the test sample;
(e) subsequently or simultaneously exposing the CTGF receptor to the CTGF receptor agonist;
(f) detecting and/or measuring the amount of CTGF receptor activation;
(g) comparing the amount of CTGF receptor activation in the presence of a test sample with the amount of CTGF receptor activation detected and/or measured in the absence of a test sample; and (h) determining if a compound reduces and/or prevents fibrosis on the basis that it causes no increase or a decrease in CTGF
receptor activation.
2. The method of Claim 1 further comprising the step of:
(i) isolation of the compound capable of reducing and/or preventing fibrosis.
(i) isolation of the compound capable of reducing and/or preventing fibrosis.
3. The method of Claim 2 further comprising the step of (j) formulating the isolated compound into a composition further comprising a pharmaceutically acceptable carrier, excipient and/or diluent.
4. The method of any previous claim wherein CTGF receptor activation is measured and/or detected by detecting and/or measuring at least one of the following activities: CTGF receptor autophosphorylation;
receptor-induced protein phosphorylation; and/or CTGF receptor induced TIEG expression.
receptor-induced protein phosphorylation; and/or CTGF receptor induced TIEG expression.
5. The method of any previous claim wherein the CTGF receptor agonist is CTGF.
6. The method of any previous claim wherein the CTGF receptor is the TrkA receptor.
7. The method of any previous claim wherein the compound affects directly with the interaction between the CTGF receptor and an agonist thereof.
8. The method of any of claims 1 to 6 wherein the compound affects indirectly with the interaction between the CTGF receptor and an agonist thereof.
9. The method of any previous claim wherein the compound is a CTGF
receptor antagonist.
receptor antagonist.
10. A compound for use in the reduction and/or prevention and/or diagnosis of fibrosis characterised in that it inhibits and/or prevents CTGF receptor activation.
11. A compound identified and/or made by the method of any one of Claims 1 to 9 for use in the reduction and/or prevention and/or diagnosis of fibrosis.
12. A compound as claimed in either of Claims 10 and 11 which is at least one selected from polypeptides, antibody molecules, antisense nucleotides.
13. A compound as claimed in Claim 12 wherein the compound is an antibody molecule.
14. A compound as claimed in Claim 12 wherein the compound is a CTGF receptor antagonist.
15. Use of a compound identified and/or made by any of Claims 1 to 9 in the treatment and/or prevention and/or diagnosis of a fibrotic disease.
16. Use of a compound identified and/or made by any of Claims 1 to 9 in the manufacture of a medicament for the treatment and/or prevention and/or diagnosis of a fibrotic disease.
17. Use of a compound as claimed in either Claim 10 or 11 in the treatment and/or prevention and/or diagnosis of a fibrotic disease.
18. Use of a compound as claimed in either Claim 10 or 11 in the manufacture of a medicament for the treatment and/or prevention and/or diagnosis of a fibrotic disease.
19. A use as claimed in any one of Claims 15 to 18 wherein the fibrotic disease is selected from one or more diabetic nephropathy, no-diabetic kidney fibrosis, lung fibrosis, liver fibrosis (cirrhosis), skeletal muscle fibrosis, cardiac muscle fibrosis, atherosclerosis, systemic sclerosis, scleroderma, retinal fibrosis, radiation induced fibrosis keloid scar formation and cancer-associated fibrosis.
20. A use as claimed in Claim 19 wherein the disease is diabetic nephropathy.
21. A method of treating and/or preventing a fibrotic disease comprising administering a therapeutically or prophylactically effective dose, or plurality of doses, of a compound identified and/or made by the method of any of Claims 1 to 9.
22. A method of treating and/or preventing a fibrotic disease comprising administering a therapeutically or prophylactically effective dose, or plurality of doses, of a compound as claimed in any of Claims 10 to 14.
23. A method as claimed in either Claim 21 or 22 wherein the fibrotic disease is selected from one or more diabetic nephropathy, no-diabetic kidney fibrosis, lung fibrosis, liver fibrosis (cirrhosis), skeletal muscle fibrosis, cardiac muscle fibrosis, atherosclerosis, systemic sclerosis, scleroderma, retinal fibrosis, radiation induced fibrosis keloid scar formation and cancer-associated fibrosis.
24. A method as claimed in Claim 23 wherein the fibrotic disease is diabetic nephropathy.
25. Use of an agent capable of binding to a CTGF receptor agonist in the treatment and/or prevention and/or diagnosis of a fibrotic disease.
26. Use of an agent capable of binding to a CTGF receptor agonist in the manufacture of a medicament for the treatment and/or prevention and/or diagnosis of a fibrotic disease.
27. A use as claimed in Claims 25 or 26 wherein the fibrotic disease is selected from one or more diabetic nephropathy, no-diabetic kidney fibrosis, lung fibrosis, liver fibrosis (cirrhosis), skeletal muscle fibrosis, cardiac muscle fibrosis, atherosclerosis, systemic sclerosis, scleroderma, retinal fibrosis, radiation induced fibrosis keloid scar formation and cancer-associated fibrosis.
28. Use of an agent capable of binding to a CTGF receptor agonist in a method of reducing and/or preventing binding of a CTGF receptor agonist to a CTGF receptor in vivo or in vitro.
29. A use as claimed in Claims 26 to 28 wherein the agent capable of binding to a CTGF receptor agonist is a CTGF receptor.
30. A use as claimed in Claims 26 to 28 wherein the agent capable of binding to a CTGF receptor agonist is a CTGF receptor joined to the Fc-region of an immunoglobulin.
31. A use as claimed in Claims 29 or 30 wherein the CTGF receptor is the TrkA receptor.
32. A use as claimed in Claims 29 or 30 wherein the CTGF receptor is a soluble form of the TrkA receptor.
33. A nucleic acid encoding the TrkA receptor joined to an Fc-region of an immunoglobulin.
34. A vector containing a nucleic acid according to Claim 33.
35. A polypeptide comprising the TrkA receptor joined to an Fc-region of an immunoglobulin.
36. A cell containing a nucleic acid according to Claim 33 and/or a vector according to Claim 34 and/or a polypeptide according to Claim 35.
37. A pharmaceutical composition comprising a nucleic acid according to Claim 33 and/or a vector according to Claim 34 and/or a polypeptide according to Claim 35 and/or a cell according to Claim 36, and a pharmaceutically acceptable carrier or exipient, the nucleic acid and/or the vector and/or the polypeptide and/or the cell being present in an effective amount to treat and/or prevent and/or diagnose a fibrotic disease.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0326780.4 | 2003-11-18 | ||
GBGB0326780.4A GB0326780D0 (en) | 2003-11-18 | 2003-11-18 | Biological materials and uses thereof |
PCT/GB2004/004795 WO2005050203A2 (en) | 2003-11-18 | 2004-11-15 | The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2546401A1 true CA2546401A1 (en) | 2005-06-02 |
Family
ID=29763971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002546401A Abandoned CA2546401A1 (en) | 2003-11-18 | 2004-11-15 | The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1718979A2 (en) |
JP (1) | JP2007515162A (en) |
CN (1) | CN1906491A (en) |
AU (1) | AU2004292013A1 (en) |
CA (1) | CA2546401A1 (en) |
GB (1) | GB0326780D0 (en) |
WO (1) | WO2005050203A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0326778D0 (en) * | 2003-11-18 | 2003-12-24 | Imp College Innovations Ltd | Biological materials and uses thereof |
US20060275797A1 (en) * | 2005-03-21 | 2006-12-07 | Alcon Manufacturing, Ltd. | Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders |
US8946172B2 (en) | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
EP3081648A1 (en) * | 2008-08-25 | 2016-10-19 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
EP2169059A1 (en) * | 2008-09-25 | 2010-03-31 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Means and methods for counteracting, preventing and/or determining fibrosis or a risk of fibrosis |
EP2221387A1 (en) | 2009-02-19 | 2010-08-25 | Université de la Méditerranée | Fibrosis susceptibility gene and uses thereof |
EP2670411B1 (en) | 2011-02-02 | 2019-04-10 | Excaliard Pharmaceuticals, Inc. | Antisense compounds targeting connective tissue growth factor (ctgf) for use in a method of treating keloids or hypertrophic scars |
CA2843949C (en) | 2011-08-05 | 2021-01-12 | Universite D'aix-Marseille | Fibrosis susceptibility il22ra2 gene and uses thereof |
KR101467109B1 (en) * | 2013-07-10 | 2014-12-01 | 영남대학교 산학협력단 | Composition for preventing or treating pulmonary fibrosis comprising BIX02189 compound |
CN106029614B (en) | 2014-02-05 | 2019-05-31 | Vm肿瘤药物有限责任公司 | Composition of compound and application thereof |
JP2022533855A (en) * | 2019-05-30 | 2022-07-26 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | Anti-TrkA antibody and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001015729A1 (en) * | 1999-08-27 | 2001-03-08 | Fibrogen, Inc. | Connective tissue growth factor receptor, its agonists and antagonists, and their therapeutic and diagnostic uses |
-
2003
- 2003-11-18 GB GBGB0326780.4A patent/GB0326780D0/en not_active Ceased
-
2004
- 2004-11-15 CN CNA2004800406378A patent/CN1906491A/en active Pending
- 2004-11-15 JP JP2006540577A patent/JP2007515162A/en active Pending
- 2004-11-15 EP EP04798515A patent/EP1718979A2/en not_active Withdrawn
- 2004-11-15 AU AU2004292013A patent/AU2004292013A1/en not_active Abandoned
- 2004-11-15 WO PCT/GB2004/004795 patent/WO2005050203A2/en not_active Application Discontinuation
- 2004-11-15 CA CA002546401A patent/CA2546401A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2004292013A1 (en) | 2005-06-02 |
WO2005050203A2 (en) | 2005-06-02 |
CN1906491A (en) | 2007-01-31 |
JP2007515162A (en) | 2007-06-14 |
WO2005050203A3 (en) | 2005-11-17 |
EP1718979A2 (en) | 2006-11-08 |
GB0326780D0 (en) | 2003-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bergeron et al. | Spatial and temporal regulation of receptor tyrosine kinase activation and intracellular signal transduction | |
Makino et al. | Blockade of PDGF receptors by crenolanib has therapeutic effect in patient fibroblasts and in preclinical models of systemic sclerosis | |
US20090123456A1 (en) | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists | |
US20030077664A1 (en) | Methods of screening for compounds that modulate hormone receptor activity | |
Kumakura et al. | Overexpression of membrane glycoprotein PC‐1 can influence insulin action at a post‐receptor site | |
Ichikawa et al. | Molecular biology of histidine decarboxylase and prostaglandin receptors | |
Boerner et al. | Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesis | |
CA2546401A1 (en) | The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis | |
JP6255156B2 (en) | Extracellular allosteric inhibitor binding domain from tyrosine kinase receptor | |
BRPI0609449A2 (en) | gdf-8 modulation agent detection | |
US6071709A (en) | Nerve growth factor/receptor complex | |
Li et al. | Prostanoid EP4 agonist L-902,688 activates PPARγ and attenuates pulmonary arterial hypertension | |
Seiler et al. | Inhibition of insulin‐like growth factor‐1 receptor and IRS‐2 signaling by ethanol in SH‐SY5Y neuroblastoma cells | |
JP2009510172A (en) | Compositions and methods for treating inflammation | |
JP2002506004A (en) | Methods and compositions for modulating leptin activity | |
Lee et al. | Differential effects of glial cell line‐derived neurotrophic factor and neurturin in RET/GFRα1‐expressing cells | |
Wakahara et al. | Bikunin down‐regulates heterodimerization between CD44 and growth factor receptors and subsequently suppresses agonist‐mediated signaling | |
Hallak et al. | Epidermal growth factor–induced activation of the insulin-like growth factor I receptor in rat hepatocytes | |
WO1998045711A2 (en) | Assay for ligands to tyrosine kinase receptors | |
Bernstein et al. | Signal transduction pathways of angiotensin II in the kidney | |
Lundgren et al. | Engineering the recruitment of phosphotyrosine binding domain-containing adaptor proteins reveals distinct roles for RET receptor-mediated cell survival | |
WO2005050202A2 (en) | Biological materials and uses thereof | |
JP2008526905A (en) | Use of TRPC channels to treat cardiovascular disease | |
US6270981B1 (en) | Methods of screening competitors of OB-R binding to SHP-2-SH2 peptides | |
WO2024013052A1 (en) | Novel use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |